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Chapter 1 
 
Introduction 
 
Pigmented lesions of the oral mucosa 
Human oral and head and neck mucosa is not uniformly coloured and several 
degrees of chromatic variegation may be observed in physiological and 
pathological conditions 1-6. The term “pigmentations of the oral and head and 
neck mucosa” may be applied to a wide range of entities caused by the 
accumulation of one or more pigments and featuring a change in colour of  
tissues 1-5, 7.  Pigments associated with mucosal discoloration can be 
subclassified into endogenous (e.g melanin and blood-related pigments) and 
exogenous (e.g. metals and drug-related pigments). Melanin-associated lesions 
represent the most common pigmentations and include benign entities as well 
as mucosal melanoma, an extremely aggressive neoplasm 1-7.  
With the exception of several studies on sinonasal, pharyngeal and conjunctival  
melanomas 8-36, most of the analyses on pigmented lesions of the head and 
neck mucosa reported in the literature are focused on the oral cavity 1-6, 37-71. 
Benign melanin-associated pigmentations of the oral mucosa include racial 
pigmentations, melanotic macules, oral melanocytic naevi (OMNs), 
melanoacanthoma, post-inflammatory pigmentations and so-called “smoker’s 
melanosis” 1-6, 37-71. Several systemic diseases such as Peutz-Jeghers and 
Laugier-Hunziker syndromes as well as the Addison’s disease are also 
characterized by the presence of benign melanin-associated lesions of the oral 
and perioral tissues 72-77. 
Non-melanin associated pigmentations may be caused by blood-related 
(bilirubin and biliverdin), iron-containing (ferritin and hemosiderin) and metal 
pigments 1-6, 78-82. Among these, amalgam pigmentation (“amalgam tattoo”) 
represent the most frequently described 78-82. Several drugs have been reported 
to induce mucosal discoloration through direct deposition on oral surfaces, local 
accumulation after systemic absorption, stimulation of melanin-related pathways 
and bacterial metabolism 1-6. 
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Clinical and histopathological diagnosis of pigmented lesions of the oral and 
head and neck mucosa may be challenging. No reliable criteria exist for the 
clinical differentiation between mucosal melanoma and a number of other 
pigmented lesions such as melanotic macules, OMNs or amalgam tattoos 1-6. 
With the exception of oral malignant melanoma (OMM), all pigmented primary 
lesions in the oral cavity are benign and treatment usually is required only when 
discomfort is present 1-6. 
 
Head and neck mucosal melanoma 
Head and neck mucosal melanomas (HNMMs) are rated among the most 
malignant tumours of the human body with a 5-year survival rate for nasal, 
pharyngeal, oral and sinus melanomas of respectively 30.9, 13.3, 12.3 and less 
than 5.0 percent 8-36. 
The incidence of HNMM is approximately four per 10 million population per year 
in the United States and this malignancy accounts for 8-15% of all head and 
neck neoplasms, including cutaneous melanoma 6,  8-10,  83,  84  . 
With regard to the subgroup of OMM, it has been reported that it accounts for 
0.5% of all oral malignancies and that its incidence is slightly higher among the 
Japanese population 83-86. 
Etiology and pathogenesis of HNMM are essentially unknown 8-36, 83-86. On the 
base of epidemiological data some authors hypothesized a possible influence of 
formaldehyde exposure 27. The close anatomic proximity of the commonly 
affected head and neck mucosal sites (nasal cavity and paranasal sinuses and 
the palate) may lead to the hypothesis that the pathogenesis of these tumours 
is related to some abnormality during the embryogenesis of this region 29. 
It has been reported that almost one third of OMMs are preceded for months or 
years by pigmented lesions but the nature of such precursors has never been 
clarified 83, 86. Since OMNs and OMM share similar epidemiologic features such 
as the frequent localization on the hard palate, it may be hypothesized that a 
particular histotype of OMN represents a potentially malignant precursor 46.  
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However, no data on the potential malignant transformation rate of OMNs are 
available as they are for the melanocytic nevi of the skin 54, 57. 
The clinical manifestations of HNMM are extremely heterogeneous. Painful 
black or brown nodules in the oral cavity and dark polypoid masses in the nasal 
and paranasal sinus cavities are the most commonly clinical features reported. 
Other unspecific signs consist of ulceration and bleeding. Few HNMM are non-
pigmented (amelanotic melanomas) 8-36, 83-86. 
From the histopathologic point of view, malignant melanoma cells show a wide 
range of shapes including spindle, clear cell and epithelioid ones. A distinction 
between “in situ” melanomas, melanomas with an invasive pattern and 
melanoma with a combined pattern has been proposed for OMMs 87. Useful 
immunohistochemical markers include S-100 protein and HMB-45 8-36, 83-86. 
The TNM clinical staging system for HNMM recognizes three stages: Stage I, 
primary tumor present only (T any N0 M0); Stage II, tumor metastatic to 
regional lymph nodes (T any N1 M0); Stage III, tumor metastatic to distant sites 
(T any N any  M1) 21, 23. 
Therapy of HNMM is commonly based on surgical excision of the primary 
tumour, supplemented by radiotherapy, with chemotherapy and immunotherapy 
serving as adjuncts 8-36, 83-86. 
Recurrent melanoma may manifest itself up to 10-15 years after primary 
therapy and distant metastases to the lungs, brain, liver, or bones are frequently 
observed  8-36, 83-86. 
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Aim of the study 
The aim of the present thesis is to report the clinical and pathological features of 
a number of pigmented lesions of the oral mucosa particularly with regard to 
malignant melanoma. 
A clinicopathological review of the recent literature on oral pigmented lesions, 
with emphasis on the main diagnostic features, including the use of 
immunohistochemical markers is presented in chapter 2. After an overview on 
embryology and histology of oral mucosal melanocytes, we analyze the oral 
pigmented lesions describing the epidemiological, clinical, histopathological and 
therapeutical aspects of a number of oral pigmented lesions. A flow-chart for 
diagnosis and some recommendations for the management  are included. 
The current knowledge on OMM is critically reviewed in chapter 3. Etiology, 
clinical and histological features, diagnostic aspects, terminology and 
classification, staging systems, prognostic factors and survival are extensively 
discussed. A section of the paper is dedicated to the analysis of the differences 
between excisional and incisional biopsies in terms of spreading of malignant 
cells. The role of surgery, including the policy with regard to the neck and the 
role or primary and postoperative radiotherapy are also reviewed. 
The experience with 14 patients with a histopathological diagnosis of OMM and 
treated at the Department of Oral and Maxillofacial Surgery/Oral Pathology of 
the VU University medical center (VUmc) in Amsterdam between 1978 and 
2005 is presented in chapter 4. 
The exceptional finding of pseudoepitheliomatous hyperplasia (PEH) in 
malignant melanoma of the palate in a 46-year-old female patient is reported in 
detail in chapter 5. A discussion on the possible histogenesis of PEH is also 
included. 
A case of melanotic pigmentation of the palatal minor salivary glands is reported 
in detail in chapter 6. Four years later the patient developed a malignant 
melanoma at the junction of the hard and the soft palate. A discussion on the  
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presumptive potentially malignant nature of the salivary glands pigmented 
lesion is included. 
The role of oral melanocytic naevi as markers for oral malignant melanoma 
development is discussed in chapter 7. The paper reports an epidemiological 
and pathological evaluation on 119 cases of OMNs registered in the nationwide 
Registry of Pathology (PALGA) in the Netherlands in the period 1980-2005. 
The experience with a group of 42 patients with a primary HNMM referred to the 
VU University medical center (VUmc) in Amsterdam, the Netherlands, and to 
the Academic Hospital of Parma University, Italy, in the last 30 years, is 
reported in chapter 8. The emphasis of the study was on the role of surgery and 
post-operative radiotherapy. 
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Abstract 
The term “pigmentation of the oral mucosa” is applied to a wide range of lesions 
or conditions featuring a change of colour of oral tissues. Lesions not 
associated with an accumulation of pigment (e.g. Fordyce’s spots) are usually 
not classified as pigmented lesions. 
Two groups of pigmented lesions of the oral mucosa are recognized :1) 
melanin-associated lesions, including racial pigmentations, melanotic macules, 
melanocytic naevi and malignant melanoma; 2) non-melanin-associated (e.g. 
blood-related pigmentations, metallic pigmentations) lesions. 
This paper presents a clinicopathological review of the recent literature with 
emphasis on the main diagnostic features, including the use of 
immunohistochemical markers. A flow-chart is added that may help the clinician 
in the diagnosis and management of these lesions. 
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1. Introduction 
Human oral mucosa is not uniformly colored and several degrees of chromatic 
variegation may be observed in physiologic and pathologic conditions 1-5. Oral 
subsites are characterised by different structural colors, depending on degree of 
keratinization, numbers and melanogenic activity of melanocytes, 
vascularization and type of submucosal tissue (muscle, bone, cartilage). The 
physiologic color of the oral mucosa thus ranges from white to red-purple in 
white-skinned people, while an evenly black to brown color of gingiva and 
buccal mucosa and the lips, are characteristic of black-skinned people 1-5. 
In this review, two groups of pigmented lesions are discussed: melanotic 
lesions, and lesions caused by other pigments. After an overview of oral 
histology and physiology of melanocytes, a flow-chart will be presented that 
may help the clinician in the diagnostic process (Figure 1). 
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Figure 1. Diagnosis and management of pigmented lesions. 
* Palate and gingiva are considered subsite at risk for OMM development. 
** In case of multiple or diffuse pigmentation(s) further examination for underlying diseases or 
syndromes (e.g. Addison’s, Peutz-Jeghers syndrome, etc.) may be considered. 
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2. Melanin-associated pigmented lesions of the oral cavity 
2.1. Oral mucosal melanocytes : histology and physiology 
Melanocytes were first identified in the oral epithelium by Becker in 1927; a few 
years later they were isolated from samples of gingival tissue by Laidlaw and 
Cahn 6, 7. During early intrauterine life, precursors of melanocytes, 
melanoblasts, migrate from the neural crest to the epidermis and the hair 
follicles, becoming differentiated dendritic cells 8-10. The head and neck region 
represents the first part of the body where melanocytes appear after 
approximately 10 weeks of gestation 10. 
Melanocytes are located in the basal epithelial layer of squamous mucous 
membranes and do not contact each other. They are regularly interspersed 
between the basal keratinocytes. Melanocytic dendrites reach a number of 
keratinocytes in the close vicinity, and through these dendrites, melanin is 
transported and transmitted to these epithelial cells 4, 11-13. An age related 
increase of oral melanocytes has been observed 14. 
The normal melanocytes of the oral mucosa have a small, round nucleus and a 
small amount of a clear cytoplasm, with slender dendrites extending between 
adjacent keratinocytes. Melanocytes are devoid of desmosomes or attachment 
plates 15. Melanin-containing electron-dense vesicles, so called melanosomes, 
are formed within the cytoplasm and transported along the dendrites 13. 
The use of 3, 4 dihydroxyphenylalanine (DOPA), a substrate for tyrosinase, 
represents the most specific histochemical method for labeling melanocytes 11. 
Other methods include argentaffinic melanin-labeling techniques such as the 
Masson-Fontana staining. Inactive oral mucosal melanocytes, lacking melanin 
and melanin precursors, may not stain with this method 11. 
Immunohistochemically, the S100 antigen is by far the most common marker 
used. S100 staining appears to be stronger in melanocytes lacking pigment. 
Another commonly used marker is HMB-45, a monoclonal antibody directed 
against a melanosomal glycoprotein 1, 14. HMB-45 is not expressed by 
melanocytes that lack all melanogenic activity 11. 
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The main biochemical function of the mature melanocyte is a process called 
melanogenesis through which the cell produces and delivers melanin pigment 9. 
Eumelanin (brown-black melanin) causes a brown-black color of the skin, hair 
and eye, while pheomelanin has a reddish color. Neuromelanin, found in some 
nerve cells, is an unrelated substance 16. 
Various stimuli such as trauma, hormonal changes, medication and radiation 
may result in an increased production of melanin 17. Melanin functions include 
absorption of ultraviolet light and scavenging of some cytotoxic compounds 13. 
 
2.2 Racial Pigmentation (physiologic pigmentation) 
No agreement exists in the literature on the definition of “race”, “racial group”, 
“ethnic group” and “ethnicity” 18. Furthermore, it has been demonstrated that the 
strength of the relationship between skin color and ancestry is quite variable. As 
a matter of fact, the melanin content of the skin does not seem to be strictly 
related to ancestry, genetically defined by the so-called “ancestry-informative 
markers” (AIMs) 18. On the basis of a multivariate evaluation, three categories of 
humans have been defined: whites, blacks and intermediates. Factors 
considered include skin color in the medial part of the arm, color and texture of 
the hair, and shape of nose and lips 19. 
Oral “racial” pigmentations (ORPs) are usually observed in dark-skinned 
populations 1-5. In a study on 1300 children, ORPs were identified in 13.5% 17. 
Pigmentations are usually diffuse and bilateral even though a variety of patterns 
have been observed 1, 3. Color ranges from light dark to brown. Gingiva, with the 
exclusion of the marginal border, and buccal mucosa are the most commonly 
involved sites (Figure 2). Other sites include lips, palate and tongue 1-5 (Figure 
3). 
Racial pigmentations are innocuous and treatment is only for aesthetic reasons. 
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2.3 Melanotic macules 
Melanotic macules of the oral cavity are relatively common lesions, caused by 
an increased production and deposition of melanin within the basal cell layer, 
the lamina propria, or both 1-3. 
In the largest series from one source, Buchner et al. reported that melanotic 
macules of the lips and oral cavity represented 86.1% (665 cases) in a group of 
773 cases of solitary melanocytic lesions and the 0.7% in a group of nearly 
90,000 biopsies from oral cavity and perioral tissues 20. Of these, 207 where 
located on the lips and 458 involved various subsites of the oral mucosa. The 
vermillion border and the gingiva were the most commonly affected subsites 
(60%). In another review, Kaugars et al. reported a prevalence of 0.4% among 
86,202 biopsies from the oral cavity. Labial lesions almost exclusively affect the 
lower lip, while gingival melanotic macules are more frequently localized in the 
anterior part of the maxilla. Black patients are more likely to have involvement of 
the buccal mucosa 21. The female to male ratio is almost 2:1 and the highest 
incidence is reported during the fifth decade 20,  21. 
Controversy exists on the pathogenetic mechanism that leads to the 
development of melanotic macules and it is not clear if they represent a 
physiologic or a reactive process 1. Some authors reported a positive family 
history and a genetic predisposition has been hypothesized 22. 
Figure 2. Racial pigmentation. Gingival 
involvement.                         
Figure 3.  Physiologic pigmentation on 
the tips of the fungiform papillae. 
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Melanotic macules are usually single, well-circumscribed blue or brown-to-black 
lesions homogeneously colored, and less than 1 cm in diameter 1, 3. Intraoral 
lesions tend to be larger than those located on the lips 1. Unlike ephelides, 
melanotic macules do not darken after exposure to sun radiation 23. 
Dermatoscopy may show a structureless pattern, characterized by a diffuse 
brown black pigmentation, seldom irregularly distributed, without pigment 
network or globules and/or streaks 24.  
The diagnosis is usually made on clinical grounds alone 1. 
From the histopathologic point of view there is absence of rete ridge elongation 
and lack of prominent melanocytic activity 1-3. Pigmentation is usually most 
marked at the tips of the rete ridges and melanophages can also be observed in 
the upper part of lamina propria. 2, 22. There is lack of atypia of melanocytes and 
HMB-45 immunoreactyivity is typically lacking 1, 3, 20, 21, 25. When melanin 
pigment is observed in the epithelium of a clinically non-pigmented lesion, the 
term “focal melanosis” has been used by some 26. 
 
2.4 Lentigines and ephelides 
The term lentigo (plural : lentigines) indicates a well-defined hyperpigmented 
lesion of the skin with an increased number of melanocytes arranged as solitary 
units along the epithelial-mesenchymal junction, without formation of nests 27. 
Lentigines are subdivided in simple lentigines and solar lentigines, the latter 
being associated with epithelial hyperplasia, which generally takes the form of 
rete ridge elongation. Melanocytic hyperplasia is minimal in solar lentigines. 
Lentigo simplex is a lesion histologically characterized by more obvious 
melanocytic hyperplasia, together with increased melanin formation 27. No clear 
data on epidemiology are available in white skinned population while lentigo 
simplex has been reported to be the most frequent pigmented lesion in acral 
sites of darkly pigmented races. Pathogenesis is most likely related to 
developmental or intrinsic defects in melanocytes homeostasis. Clinical features 
of lentigo simplex include light to dark brown pigmentation, usually sharply  
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circumscribed. Lesions can be single or multiple, the latter situation being 
associated with a number of rare syndromes 27. 
Different from lentigo simplex, solar lentigines (synonyms sun-induced freckles, 
lentigo senilis) are ultraviolet (UV)-induced pigmented lesions. Epidemiology 
shows an increased incidence among the general population over 60 years of 
age 1, 3. 
Ephelides (freckles) are small (less than 1 cm) red or light-to dark-brown 
macules localized on sunexposed areas of the body 2, 28. They typically affect 
white-skinned individuals, are multiple, and uniform in color and regular in 
outline, although confluence leads to irregularly shaped larger patches 2. 
Ephelides may appear at any age but most frequently occur in childhood 2, 28. 
They wax and wane with the degree of solar exposure, being most conspicuous 
in the summer months. 
No data exist on the prevalence of intraoral lentigines and ephelides; they 
mainly affect the vermillion border of the lips or the perioral tissues 2. 
 
2.5 Melanocytic Naevi 
Oral melanocytic naevi (OMNs) are benign tumors of melanocytes 27. 
Approximately 500 cases have been reported in the English literature; no 
systematically assembled data on their frequency are available 20, 29. A recent 
report from the Netherlands revealed an annual incidence of excised OMNs of 
4.35 cases per 10 million population per year 29. 
The etiology and pathogenesis of OMNs are poorly understood even though, as 
for their cutaneous counterpart, oncogenic mutations of genes coding for 
components of the RAS signaling pathways may play a role 30. 
Regarding morphogenesis, the melanocytic proliferation can be divided into 
three phases: 1) proliferation of benign neoplastic melanocytes along the 
epithelial-mesenchymal junction (junctional naevus); 2) migration of these cells 
into the mesenchymal compartment (compound naevi); and 3) loss of the 
junctional component of the naevus, so that all remaining nevomelanocytes are  
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located within the subepithelial compartment (subepithelial naevi) 12, 27, 31 
(Figure 4). These steps correspond to the histologic variants of OMNs 29. Less 
common naevus subtypes include blue naevus (Figures 5 and 6), combined 
naevus and Spitz naevus 32-36. 
 
Figure 4. Histopathological features of subepithelial naevus. All nevomelanocytes are 
confined within the subepithelial compartment (H&E stain; orig. magn. x50). 
 
 
 
 
 
In the histopathological evaluation, the additional use of immunohistochemical 
stains may be required, such as the melanocytic markers Melan A, HMB45 and  
Figure 5. Blue naevus of the palate. Figure 6. Histopathological features of 
a blue naevus. Spindle- shaped  
nevomelanocytes (Schmorl stain: 
orig. magn x 150). 
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microphthalmia transcription factor (mitf). In melanin pigment laden cells, 
additional markers, e.g. CD68, a marker for macrophages, may be helpful in 
identifying the nature of such cells. Such a procedure may be particularly helpful 
in arriving at a correct diagnosis of a blue naevus. 
Congenital melanocytic naevi are present at birth, while those developing after 
birth are referred to as acquired naevi 37-39. Probably, most melanocytic naevi of 
the oral mucosa are acquired, 37 even though some cases of congenital naevi 
have been reported 38. Sizes range from 0.1 to, rarely, 3.0 cm 37, 40. OMNs 
typically are well circumscribed round or oval macules or papules, but polypoid 
larger lesions have been reported as well 27, 37, 40. OMNs have been reported to 
occur in a multiple fashion 41. Elevated acquired naevi are usually lightly 
pigmented, while flatter lesions tend to be more darkly pigmented 27. Colors 
vary from brown to blue, bluish-gray, or black; generally an individual lesion has 
a similar color throughout 27, 37, 40, 42. Rare non-pigmented naevi are on record 43. 
The hard palate, buccal mucosa and gingiva are most commonly affected 37, 40, 
42, 44, 45. 
Despite a strong epidemiological correlation between OMNs and OMMs with 
regard to age, gender predisposition and oral subsites, there is no proof that 
naevi of the oral mucosa are markers of the development of malignant 
melanoma 29. 
 
2.6 Melanoacanthoma 
The term melanoacanthoma has been used to describe a rare, benign mixed 
lesion of keratinocytes and pigmented-laden dendritic melanocytes 46-48. Oral 
melanoacanthoma is thought to have a reactive nature and usually regresses 
spontaneously or after incomplete removal, such as incisional biopsy 46-48. 
Approximately 40 cases of oral melanoacanthoma have been reported 46. 
Differently from its cutaneous counterpart, oral lesions occur almost exclusively 
in Blacks, affect a much younger population, develop rapidly and generally have 
a flat surface. The buccal mucosa is the most frequently affected subsite. 
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2.7 Tobacco-associated melanin pigmentation (smoker’s 
melanosis) 
Smoking has been found to cause diffuse oral melanin pigmentation in 
European and Asian population 49-52. It has been reported in 21.5% of smokers 
and the intensity of the pigmentation is related to the number of cigarettes 
consumed 51. Some authors noticed a significant increase in gingival melanosis 
of children with parents who smoke 53. Smoker’s melanosis seems to be directly 
related to a stimulant effect of substances in smoke on melanocytes. In parallel 
to a model accepted for the skin, some authors hypothesized that melanin may 
play a role in detoxification of polycyclic amines nicotine and benzopyrene 49, 50. 
Subsites involved are mainly gingiva, hard palate, buccal and commissural 
mucosa, inferior surface of the tongue and lip mucosa (Figure 7). Smoker’s 
melanosis is usually black-brown  49-52 . 
From a histologic point of view, increased melanin is found in the basal layer of 
the epithelium, and there may be melanophages in the subjacent connective 
tissue. No melanin is detected in the upper part of the epithelium 54. Smoker’s 
melanosis does not require treatment and disappearance has been reported 
after cessation of the smoking habit 1, 49. 
 
Figure 7. Smoker’s melanosis of the lower lip. 
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2.8 Malignant Melanoma 
Oral malignant melanoma (OMM) is an aggressive tumor of melanocytes, 
accounting for 0.5% of all oral malignancies 55, 56. The neoplasm is more 
common in Japan and Africa than in Western countries 57-59. The etiology of 
OMM is unknown. Tobacco use and chronic mechanical irritation resulting from 
ill-fitting dentures have been mentioned as possible risk factors 57, 60. Most 
OMMs arise de novo, from apparently normal mucosa, but about 30% are 
preceded by oral pigmentations for several months or even years 57, 61. 
The initial symptom and sign of OMM is the emergence of a mass lesion, which 
is usually pigmented. OMM may be uniformly brown or black, or may show 
variation of color, with black, brown, grey, purple and red shades, or 
depigmentations 62. Satellite foci occasionally surround the primary tumor. In 
amelanotic melanomas, pigmentation is absent 55, 56 (Figure 8). The most 
frequently affected oral sites are the palate and the maxillary gingiva 12, 62. 
 
Figure 8. Amelanotic melanoma of the palate. 
 
OMMs probably originate from junctional melanocytes; in its first phase of 
development, the cells are restricted to the epithelial compartment: in situ 
melanoma. Subsequently, melanoma cells invade the underlying tissues 62.  
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Melanoma cells show a wide range of shapes, including spindle, plasmacytoid, 
and epithelioid ones. Clear cell change is occasionally seen 56, 62, 63.OMM is not 
subdivided into the classical cutaneous melanoma categories, which include 
superficial spreading melanoma (SSM), nodular melanoma (NM) and acral 
lentiginous melanoma (ALM). There is, however, often some similarity to ALM 
and NM 12, 59, 62, 64. The histological microstaging system of Clark, used in 
cutaneous melanoma, can not be applied to oral mucosa because of the lack of 
histologic landmarks analogous to papillary and reticular dermis 12, 62. Tumor 
thickness does not appear to be associated with prognosis 63. The TNM clinical 
staging system for OMM recognizes three stages: Stage I, primary tumor 
present only (T any N0 M0) ; Stage II, tumor metastatic to regional lymph nodes 
(T any N1 M0); Stage III, tumor metastatic to distant sites (T any N any M1) 56. 
In different series, the actuarial-5 year overall survival rate for head and neck 
mucosal melanoma ranges from 21% to 40% and for OMM it is 15%, with a 
median survival of 25 months 12, 58. Gingival melanoma has a better 5-year 
survival rate than the palatal one, with a longer median survival period (46 
months vs. 22 months) 12. Recurrent melanoma may manifest itself up to 10-15 
years after primary therapy 65. Distant metastases often affect the lungs, brain, 
liver, or bones 66. 
 
 
3. Systemic disorders associated with the presence of oral 
pigmented melanocytic lesions 
3.1 Peutz-Jeghers and other familial hamartoma syndromes 
The Peutz-Jeghers syndrome (PJS) consists of mucocutaneous macules, 
intestinal hamartomatous polyposis and increased risk of carcinomas of the 
gastro-intestinal tract, pancreas, breast and thyroid 67-68. The disease is 
associated with germline mutations in the LKB1/STK11 gene, located on the 
short arm of chromosome 19, 68-69. 
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Black-to-brown spots of less than 1 mm in size are typically localized on the 
lower lip and in the perioral area (Figure 9). Intraoral, intranasal, conjunctival 
and rectal pigmented lesions as well as spots localized on the acral surfaces 
may also be present 1-3, 68. 
The oral lesions are benign and histologically characterized by an increase in 
melanin in the basal layer, without an obviously increased number of 
melanocytes 1, 2. A fading or a disappearance of the spots is usually observed in 
older age 70. Interestingly, perioral lesions tend to persist 1. 
So-called “PTEN hamartoma tumor syndromes” (PHTS), characterized by 
mutations in the tumor suppressor gene PTEN (phosphatase and tensin 
homologue deleted on chromosome 10) include several rare diseases such as 
the Ruvalcaba-Myhre-Smith and the Cowden syndrome 68. Perioral lentigines 
have occasionally been reported in these 2. 
 
Figure 9.  Perioral involvement in Peutz-Jegher’s syndrome. 
 
3 .2 Addison’s disease and other endocrine disorders 
Primary hypoadrenalism caused by autoimmune disease, infection or 
malignancy, also referred to as Addison’s disease, is characterized by deficient 
production of hormones of the adrenal cortex, leading to increased production  
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of adrenocorticotropic hormone (ACTH) 71. This may result in a diffuse dark 
pigmentation of the skin and the oral mucosa 2, 72. Other signs and symptoms of 
Addison’s disease include anorexia, nausea and postural hypotension. 
Lips, gingival, buccal mucosa, hard palate and tongue are usually involved 
(Figure 10). Pigmented lesions may be diffuse or localised and usually precede 
skin manifestations 2, 3. 
Diffuse or discrete pigmentations of the lips and oral mucosa are sometimes 
observed in monostotic and polyostotic fibrous dysplasia (McCune-Albright 
syndrome), hyperthyroidism and Nelson’s syndrome 2. 
Treatment of pigmented lesions of the oral mucosa associated with a systemic 
disorder is usually not required unless discomfort is present. The disappearance 
of oral lesions may follow the treatment of the underlying condition. 
 
Figure 10. Oral Manifestation of Addison’s disease (Courtesy of dr. J.van 
 Hooff, The Netherlands).  
 
3.3 Other conditions 
Oral melanocytic pigmentations have been reported in patients with Laugier-
Hunziker syndrome (idiopathic lenticular mucocutaneous pigmentations) and  
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with Carney complex (spotty skin pigmentations, myxomas and endocrine 
overactivity) 2, 73-77. 
HIV infection has been associated with multiple, usually well-circumscribed 
melanotic macules localized on the buccal and palatal mucosa, gingiva and lips 
5. However, the association may be only coincidental. The histolopathological 
appearance is similar to classical melanotic macules. It remains unclear 
whether such pigmentations are caused by the virus, by therapy, or other 
factors 1, 2, 78. 
Chronic inflammatory conditions such as oral lichen planus, pemphigus, 
pemphigoid or chronic periodontal disease are sometimes associated with 
deposition of melanin within the connective tissue resulting in a darkening of the 
mucosal area 1, 4. These phenomenon is mostly observed in dark-skinned 
individuals 3. Fixed drug reaction after administration with cotrymazole, 
tetracycline, colchicine, ketoconazole has also been associated with post-
inflammatory hyperpigmantation 3, 79. It is debatable if these reactions only 
depend on melanin. 
The presence of lesions resembling melanotic macules of the palate in patients 
with lung diseases, including cancer, has also been reported, but there is lack of 
evidence on a true association 80. 
Melanin production and stimulation may sometimes also follow surgical 
procedures 4. 
 
 
4. Non-melanin-associated pigmented lesions of the oral 
cavity 
4.1 Lesions caused by endogenous pigments (blood-related 
pigmentations) 
Extravasations of blood in hematomas, petechiae, purpurae and ecchymoses 
may cause pigmentation 3, 81 as a result of accumulation and degradation of  
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haemoglobin to bilirubin and biliverdin 3. Color of the lesions depend on length 
of time from trauma and may range from red to black. Typical traumatic events 
in the oral cavity possible associated with blood extravasations and 
hyperpigmentation include biting, traumas with eating and iatrogenic 
procedures. 
Patients with haemochromatosis (“bronze diabetes”) frequently display bluish-
grey pigmentation of the hard palate, gingival and buccal mucosa 2, 4 (Figure 
11). The pigmentation is caused by deposition of iron containing pigments 
(ferritin and hemosiderin) within the skin and mucous membranes 4. Similarly, a 
diffuse black-brown pigmentation, most commonly in the junction between the 
hard and soft palate, may be observed in patients with beta-thalassemia 1. 
 
Figure 11. Palatal pigmentation in a patient with hemochromatosis. (Courtesy of dr. J.G.N. 
Swart, The Netherlands). 
 
4.2 Lesions caused by exogenous pigments (metallic 
pigmentations) 
4.2.1 Amalgam pigmentation (amalgam tattoo) 
Accidental displacement of metal particles in oral soft tissues during restorative 
dental procedures using amalgam may result in amalgam pigmentation, the  
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so-called “amalgam tattoo” 1-5. Terms such as focal argyrosis or oral localized 
argyria should be avoided, since not only silver, but also mercury and tin are 
contained in the amalgam alloy. 
Despite the high prevalence of these lesions among the general population, 
little information is available in the dental literature. Buchner and Hansen 
identified 268 (1.3 %) amalgam tattoos among 20.731 specimens from the oral 
cavity 82. The etiology of amalgam tattoos can be iatrogenic or traumatic. Metal 
particles may over time leach in the soft oral tissues, resulting in the 
discoloration. Buchner and Hansen and Owens et al. listed several iatrogenic 
and traumatic modalities through which amalgam may be introduced in the oral 
tissues: condensation of the material in abraded mucosa during routine 
amalgam restorative work; introduction of the material within the lacerated 
mucosa during removal of amalgam fillings or crowns and bridges; introduction 
of broken pieces into a socket or the periosteoum during extraction of teeth; 
introduction of metal particles in a surgical wound during root canal treatment 
with a retrograde amalgam filling 82, 83. 
Amalgam tattoos usually range from 0.1 up to (rarely) 2 cm in size and can be 
solitary or multiple. Colors reported are blue, grey or black with a spectrum of 
variegation depending on the depth of metal within tissues. Gingiva and alveolar 
mucosa are the subsites most frequently involved. In alveolar edentulous 
ridges, amalgam tattoos can also be associated with restored antagonistic teeth 
(Figure 12). The diagnosis is based on clinical findings and the relationship with 
present or removed amalgam restorations. 
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Figure 12. Amalgam tattoo. 
 
Radiographic features may show localized radiopacities 1. Biopsy is indicated 
only when suspicion of OMM can not be ruled out on clinical grounds alone. 
Histopathologic investigation reveals amalgam particles dispersed in the 
connective tissue and sometimes in the walls of vessels. These particles may 
also line the basement membrane of the surface epithelium. Brownish granules 
within phagocytic cells and fibroblasts cytoplasm can also be observed 82, 84, 85. 
A spreading of these pigmented lesions mediated by local migration of 
phagocytic cells containing metal has also been described 1-3 , 82-84. 
Histopathologic examination of an amalgam tattoo is usually diagnostic because 
of the size and shape of the metal particles and the way they are spread in the 
tissue. However, in rare cases, one may need additional stains. The common 
melanin and iron stains are often not sufficient for differentiating between metal 
particles and melanin pigment. Instead, immunohistochemical markers such as 
HMB-45 and Melan A are more suitable for this purpose. 
When dealing with metal pigmentation, one may be able to identify the type of 
metal(s) by using electron-probe micro-analysis. 
There is no indication for complete removal of an amalgam tattoo. 
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Accidentally or voluntary introduction of other foreign particles include graphite 
from pencil tips, tattoo inks and chronic contact with charcoal toothpaste and 
vegetables, such as Juglans regia, Cola Nitida and Catha Edulis 1, 2, 86. 
 
4.2.2 Heavy metals 
Systemically absorbed metals may induce discoloration of the oral mucosa, 
caused by peripheral metal accumulation. These conditions were frequent in the 
past as result of occupational exposures to certain drugs. Arsenic, lead, 
bismuth, mercury, silver and gold are the metals most frequently involved 1-5. 
Bismuth was typically used for the treatment of syphilis and its administration 
was associated with diffuse oral pigmentation and formation of a blue-black line 
at the marginal gingival 1. A characteristic feature of plumbism (lead poisoning) 
is the so-called “Burtonian line”, a grey linear area of discoloration below the 
gingival margin 1, 3, 4 (Figure 13). Silver (argyria) and gold (chrysiasis) may 
produce slate-grey oral pigmentation and purple gingival discoloration, 
respectively 2. 
Heavy metal intoxication can be associated with a wide range of systemic signs 
and symptoms 1, 3. 
 
 
Figure 13. Oral manifestation of lead poisoning (“Burtonian line”). 
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5. Drugs associated with pigmented lesions of the oral cavity 
(excluding heavy metal containing drugs) 
Many non-heavy metal containing drugs can induce discoloration of oral tissues 
1-5, 87 . Direct deposition on oral surfaces, local accumulation after systemic 
absorption, stimulation of melaninrelated pathways, bacterial metabolism, alone 
or in combination, may result in oral pigmentations. 
The most commonly reported drugs are listed in table 1. 
 
Table 1. Drugs potentially associated with oral pigmentations. (Ref. 2 and 3) 
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6. Discussion and proposal of a flow-chart 
Diagnosis of pigmented lesions of the oral cavity and perioral tissues is 
challenging 1-5. Even though epidemiology may be of some help in orientating 
the clinician and even though some lesions may confidently be diagnosed on 
clinical grounds alone, such a diagnosis remains “provisional”. Definitive 
diagnosis usually requires histopathological evaluation. Occasionally, 
immunohistochemical stains such as melanocyte marker HMB-45 and 
marcophage marker CD68 may be required to arrive at a correct diagnosis. 
With the exception of OMM, all pigmented primary lesions in the oral cavity are 
benign and treatment usually is required only when discomfort is present. No 
reliable criteria exist for the clinical differentiation between OMM and a number 
of other pigmented lesions such as melanotic macules, oral melanocytic naevi 
or amalgam tattoos 1-5. 
The so-called ABCD checklist (“Asymmetry”, “Border” irregularities, “Color” 
variegation and “Diameter” > 6mm) that is commonly used to aid in the 
identification of cutaneous melanoma may be of some help in the clinical 
diagnosis of oral melanoma 88, 89. Rapidly growing pigmented lesions should 
always be biopsied 1. 
Location on the palate increases the rate of suspicion of melanoma and usually 
requires a biopsy or long-term follow-up. When located on the gingiva, the main 
differential diagnosis is between amalgam tattoo and melanoma. In case of the 
slightest doubt a biopsy should be taken. 
In figure 1 a flow-chart is depicted that may help the clinician in the diagnostic 
pathway of pigmented lesions of the oral cavity. When history allows to classify 
a lesion as melanocytic, a subclassification should be made, according to the 
clinical suspicion of malignancy (ABCD checklist, recent history, age and 
subsite involved). Lesions presenting “no or low suspicion of malignancy” may 
be confidently diagnosed on clinical grounds alone (e.g. oral manifestations of 
systemic diseases, physiologic pigmentations, smoker’s melanosis) or may 
require histopathological evaluation. 
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Some non-melanocytic lesions such as ethnic tattoos or pigmentations 
associated with heavy metal poisoning are easily recognized on clinical grounds 
(e.g. Burtonian line). In other cases such as an bluish discolorations not clearly 
related to amalgam restorations and/or not showing radiological signs for the 
presence of metal particles, histopathological evaluation is needed to reach a 
firm diagnosis. 
A biopsy or referral to a specialist for further evaluation is indicated if the history 
does not allow to distinguish between melanocytic and non-melanocytic lesion. 
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Abstract 
Primary oral malignant melanoma (OMM) is a rare neoplasm, accounting for 
0.5% of all oral malignancies. The etiology is unknown; tobacco use and chronic 
irritation may play some role. Clinically, OMM may mimick other pigmented 
lesions. A biopsy is required in order to establish the diagnosis. The reported 
risk of malignant cells spreading during invasive procedures and factors such as 
size of the lesion or anatomical limitations, may influence the diagnostic surgical 
procedure. Therapy of OMM is commonly based on surgical excision of the 
primary tumour, supplemented by radiotherapy, with chemotherapy and 
immunotherapy serving as adjuncts. Prognosis is poor, with a 5-year survival 
rate of approximately 15%. 
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1. Introduction 
Malignant melanoma is a potentially aggressive tumour of melanocytic origin 1. 
The incidence of head and neck mucosal melanomas (HNMM) is approximately 
four per 10 million population per year in the USA 2. Only about 1% of all 
melanomas arise in the oral mucosa and these account for 0.5% of all oral 
malignancies 2-4. The most frequently affected oral sites are the palate and the 
maxillary gingival 2, 5. Oral metastasis of melanoma, derived from a primary 
elsewhere in the body, is extremely rare and will not be discussed here. 
The age of reported patients ranges from 20 to 80 years; some authors have 
reported a male preponderance 4, 5. The neoplasm is more common in Japan 
and Africa than in Western countries 4, 6-9. Therapy is commonly based on 
combinations of surgery, radiotherapy and chemotherapy 5, 6, 10. The prognosis 
of OMM is poor, with a 5-year survival of about 15% 2. 
The present review is based on a critical analysis of the relevant literature of the 
past decades. 
 
2. Etiology 
The etiology of OMM is essentially unknown. Tobacco use and chronic irritation 
from ill-fitting dentures have been mentioned as possible risk factors 3,4, but the 
evidence is weak. Ingested and inhaled environmental carcinogens at high 
internal body temperature may play some role 11. Most OMMs arise de novo, 
from apparently normal mucosa, but about 30% are preceded by oral 
pigmentations for several months or even years 4, 12. Some of these flat 
precursor lesions consist of cytologically atypical melanocytes and may in fact 
constitute the preinvasive macular phase of melanoma. However, in other 
lesions a preexistent, histologically benign melanocytic proliferation accounts for 
the pigmentation. 
The histological spectrum of benign melanocytic lesions of the oral mucosa is 
varied, and includes so-called mucosal melanosis, i.e., a junctional proliferation 
of melanocytes with or without cytological atypia, resulting in a macular  
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hyperpigmentation, and a variety of melanocytic naevi. The latter comprise 
junctional, compound and subepithelial naevi as well as a variety of blue and 
combined naevi, which are proportionally more common than in the skin. Some 
melanoma-associated antigens become expressed during the transformation 
process from a benign melanocytic nevus to melanoma; most of these are 
related to the melanin production process and most are HLA-restricted 2. p53 
protein alterations have been identified in about two-thirds of OMM 13. A recent 
study demonstrates that loss of heterozygosity at 12p13 and loss of p27KIP1 
protein expression contribute to melanoma progression 14. Cytogenetic analysis 
and evaluation of melanocyte-specific gene-1 (MSG-1) appears to be very 
helpful for understanding the pathogenesis of OMM 15, 16. 
 
3. Clinical features 
The initial symptom and sign of OMM is often swelling, which is usually 
pigmented. OMM may be uniformly brown or black, or may show variation of 
colour, with black, brown, grey, purple and red shades, or depigmentations 5. 
Satellite foci may surround the primary. In amelanotic melanomas, pigmentation 
is absent 17. The tumour surface may be smooth, with an intact overlying 
mucosa, or may be ulcerated. Other presenting signs and symptoms include 
bleeding, ill-fitting dentures, pain, increased mobility of teeth and delayed 
healing of extraction sockets. Regional lymphadenopathy may be present and 
connotes a poor prognosis 1, 18.  
Tanaka et al. identified five types of OMM on the basis of the clinical 
appearance: pigmented nodular type, nonpigmented nodular type, pigmented 
macular type, pigmented mixed type and nonpigmented mixed type 17, 19 , 20.  
 
4. Diagnostic aspects 
Oral melanocytic pigmentations can be observed in dark skinned persons 
(“racial pigmentations”), in Peutz–Jeghers syndrome 21, in Addison’s disease 22, 
and in some patients with pulmonary disease, including lung cancer 23. The so-  
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called ABCD checklist (“Asymmetry”, “Border” irregularities, “Colour” variegation 
and “Diameter” > 6 mm) that is commonly used in the identification process of 
cutaneous melanoma 24 could also be of some help in the diagnosis of oral 
melanoma 25. When an oral pigmentation cannot be confidently diagnosed as 
benign on clinical grounds, a biopsy is mandatory in order to exclude OMM 1, 25, 
26.  
Greene et al. proposed three criteria for the diagnosis of primary OMM: 
demonstration of malignant melanoma in the oral mucosa; presence of so-
called ‘junctional activity’ (i.e., melanocytes arranged along the basal layer of 
the surface epithelium) in the lesion; inability to show malignant melanoma at 
any other primary site 27. However, the presence of ‘junctional activity’ is now 
known to be an unreliable indicator that the lesion is a primary one, since 
melanoma metastases may similarly involve the epithelial junction. Delgado et 
al. proposed a simple clinical method (“rubbing a gauze”) for the diagnosis of 
OMM but the value of such procedure seems somewhat questionable.28, 29 In a 
report by Garzino-Demo et al. cytological examination and brushed samples 
were negative in all their cases with a proven histological diagnosis of OMM 30. 
It should be borne in mind that in cutaneous melanoma, fine needle aspiration 
or exfoliative cyotology of primary pigmented lesions is contraindicated. 
Radiological examination through computed tomography, magnetic resonance 
imaging or positron emission tomography (PET) could be useful for evaluation 
of primary tumour and regional or distant metastases. In a study on 10 patients, 
Goerres et al. found that PET may be suitable for the staging of patients with 
HNMM 31. 
 
4.1 Excisional versus incisional biopsy 
The current guidelines for the surgical management of primary cutaneous 
melanoma recommend a diagnostic excisional biopsy of the lesion followed by 
a wide local excision where the diagnosis is proven 32-34. However, in the oral 
cavity, the size of the lesion or anatomical limitations, particularly the presence  
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of teeth, may preclude the taking of an excisional biopsy. Younes et al. 
proposed to take an excisional biopsy with a 1- to 2-mm margin for small 
lesions in amenable locations, but incisional biopsy, through the thickest or the 
most suspicious part of the tumour, in case of a large lesion or a location in 
sites where an excisional procedure would involve extensive and mutilating 
surgery 25 ,35.  
It has often been suggested that cutting into a malignant neoplasm during an 
incisional biopsy or other invasive procedure, could result in accidental 
dissemination of malignant cells within the adjacent tissues (“seeding”) or even 
in the blood or lymphatic stream, with the subsequent risk of local recurrence, or 
regional or distant metastasis 36-38. However, in a retrospective study of 265 
patients who had an incisional biopsy of cutaneous melanoma and 496 control 
cases of excisional biopsy, no such correlation was found 26. These findings are 
in agreement with similar studies by Lederman and Sober 39 and by Lees and 
Briggs 40. On the other hand, Rampen et al.41 and Austin et al.35 did find a 
somewhat reduced survival rate in patients with melanoma who had incisional 
biopsies. 
Some authors have postulated that a stimulation of tumour outgrowth through 
release of fibroblast growth factor (FGF) during wound healing could result from 
the surgical procedures, but this hypothesis has not been supported by results 
from other studies 42.  
 
5. Histologic features 
The 1995 WESTOP (Western Society of Teachers of Oral Pathology) Banff 
Workshop on OMM drew attention to the fact that most OMMs are discovered 
and biopsied in an advanced stage, which probably contributes to the 
heterogeneity of microscopic patterns 5.  
Like cutaneous melanoma, OMM probably has in many cases an initial phase 
characterized by radial growth followed by a phase of invasion of the underlying 
tissues (the so-called ‘vertical growth phase’). 
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OMMs can be histologically subclassified into: (1) in situ melanoma, which is 
limited to the epithelium and the epithelial–connective tissue interface; (2) 
melanomas with an invasive pattern, in which the neoplasm extends into the 
connective tissue; (3) melanomas with a combined pattern of invasive 
melanoma with in situ component 5. Malignant cells of OMM show a wide range 
of shapes, including spindle, plasmocytoid, clear cell and epithelioid ones 5, 43.  
The surface epithelium may be flattened and there may be ulceration; 
conversely, some OMMs induce pseudoepitheliomatous hyperplasia of the 
mucosal epithelium 44, 45. Shivas and Maclennan46 described the presence of 
melanin pigment in the ductal epithelial cells of the underlying salivary glands, 
using the term“melanogenic metaplasia”. 
Usually, OMM can be diagnosed with confidence on H&E-stained sections. If 
pigment is completely absent immunohistochemical stains are of significant 
help. Useful markers include S-100 protein, gp100 (HMB-45), Mart-1 (Melan-
A).6, 47, 48 
OMM does not fit well into any of the classical cutaneous melanoma categories 
like superficial spreading melanoma (SSM), nodular melanoma (NM) and acral 
lentiginous melanoma (ALM). There is, however, often some similarity to ALM 
and NM.2, 5, 9, 49 
The pathology report should include all information necessary for further 
treatment planning, such as the extent of tumour, tumour spread in relation to 
underlying and surrounding tissues, and a statement on the completeness of 
resection. In many centers, some additional information of established or 
possible prognostic significance will be added: tumor thickness, presence of 
ulceration and necrosis, tumor mitotic rate (TMR), vascular invasion 47. Finally, it 
is advisable to specify cell morphology and tumour tissue architecture 47, 50, 51.  
 
6. Terminology and classification 
The term atypical melanocytic proliferation has been used in case of oral 
melanocytic lesions in which microscopic evaluation does not result in an  
 60
Chapter 3 
 
unequivocal diagnosis. Atypical melanocytes have been defined as 
melanocytes with hyperchromatic and angular nuclei, but with infrequent mitotic 
figures 2, 5. In some studies this histologic pattern has been called “atypical 
melanocytic hyperplasia” 2. However, since the word “hyperplasia” suggests a 
reactive rather than a neoplastic origin, the term “proliferation” seems to be 
preferred here. 
Lentigines are small, round to oval, brown or black macules. In the skin several 
types of lentigo such as lentigo simplex (LS), and lentigo maligna (LM) 52 are 
recognized. The term “lentigo” alone has sometimes been used to refer to 
lentigo simplex.21, 52 LS is histologically characterized by heavy pigmentation of 
the basal layer, with increased numbers of basal melanocytes, typically, but not 
always, associated with elongation of the rete ridges.21, 52 
LM is a cutaneous lesion occurring in sun-damaged skin, usually in elderly 
persons, most frequently on the face. Histologically, it consists of a proliferation 
of atypical melanocytes, in lentiginous patterns, within a flat and atrophic 
epidermis, and often extending into cutaneous adnexae. LM is generally 
regarded as the pre-invasive phase of lentigo maligna melanoma (LMM) 21, but 
it should be realized that only a very few percent of cases, if untreated, will 
progress to invasive melanoma.52 LM has also been referred to as morbus 
Dubreuilh, or Hutchinson’s freckle.9, 52, 53 The term LM should not be applied to 
lesions of the oral mucosa, because of absence of sun damage at that site 52.  
The term melanoacanthoma has been used to describe a benign mixed tumor 
of keratinocytes and pigmented-laden dendritic melanocytes. In contrast to 
cutaneous melanoacanthoma, oral lesions occur almost exclusively in Blacks, 
affect a much younger population, develop rapidly and generally have a flat 
surface. Oral melanoacanthoma is thought to be reactive in nature, and 
regression is usually observed after elimination of traumatic factors 52, 54, 55.  
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7. Staging system 
The histological microstaging system of Clark, used in cutaneous melanoma, 
cannot be applied to oral mucosa because of the lack of histologic landmarks 
analogous to papillary and reticular dermis.50, 56, 57 
The 2002 (revised) TNM Melanoma Staging System of the American Joint 
Committee on Cancer, applying the T-symbol for the thickness and the 
ulceration status of the tumour, the symbol N for the regional lymph nodes, the 
symbol M for distant metastases and the serum lactic dehydrogenase (LDH) 
level,58 does not provide specific guidelines for OMM. 
A simple TNM clinical staging system for HNMM (including OMM), shown in 
Table 1, recognizing three stages, has shown to be of prognostic value.10, 50, 51, 
59 A recent histopathological microstaging for Stage I subclassifies three levels 
(Table 1) 50.  
 
Table 1. Clinical Staging System for OMM with histopathological microstaging for Stage I  
Stage I: Primary tumour present only (Tany N0M0) 
Level I: Pure in situ melanoma without evidence of invasion or in situ melanoma with 
“microinvasion” 
Level II: Invasion up to the lamina propria 
Level III: Deep skeletal tissue invasion into skeletal muscle, bone or cartilage 
 
Stage II: Tumour metastatic to regional lymph nodes (Tany N1M0) 
 
Stage III: Tumour metastatic to distant sites (Tany Nany M1) 
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8. Treatment 
Treatment of OMM is still controversial and there is no consensus regarding the 
best therapeutical approach 6, 10, 60. Data from several studies indicate radical 
resection of the primary as the treatment of choice 5, 6, 10, 51, 61, 62. Surgery could 
be combined with radiotherapy, chemotherapy or immunotherapy even though 
the effectiveness of such therapies both as primary or in association with the 
surgical treatment is mostly unknown. 
 
8.1 The role of surgery, including the policy with regard to the neck 
Unlike cutaneous melanoma, where randomized clinical trials have been carried 
out to establish the optimal width of the tumour-free margins, no guidelines are 
available for the surgical treatment of OMM. A protocol adopted by Umeda and 
Shimada 63 refers to the extent of the margins: 
1. excision of the primary lesion, preferably using an intraoral approach and 
involving at least 1.5 cm of healthy tissue. 
2. Excision of any lymph node metastases (Stage II). 
3. Consider chemotherapy. 
Unfortunately, local control is not a strong predictor for survival 10. Many 
patients with a presumptive radical excision of tumours develop a recurrence 5, 
which may be explained by the presence of atypical melanocytes in the surgical 
margins and/or the presence of satellites 6.  
Controversy still remains on the issue of prophylactic neck dissection 3, 64. 
Patients with primary OMM present lymph node metastasis in 25% of cases and 
this incidence is higher than HNMM at other sites 51. According to Tanaka et 
al.,60 neck dissection should be reserved for cases with preoperatively 
confirmed lymph node metastases and the choice of the neck dissection 
modality should be guided by the extent and the level of the nodes. There is no 
proof that elective nodal dissection improves survival. To our knowledge, no 
data are available on the issue of the sentinel node biopsy or on the use of PET 
scanning in OMM except from the study of Goerres et al 31.  
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8.2 The role of primary and postoperative radiotherapy 
Most of the studies on the effects of primary radiotherapy have been performed 
on the entire group of HNMM and specific data on OMM are scarce 51, 65. In a 
study on 35 patients with OMM, Tanaka et al. observed a 5-year cumulative 
survival rate of 35.5% in the group of patients treated with irradiation alone, 
while it was 15.4% for patients treated with surgery 60. Postoperative 
radiotherapy is generally recommended if poor prognostic pathologic features 
are present, such as multiple positive nodes, or extranodal spread of 
metastastic melanoma, even though OMMs are regarded as poorly 
radiosensitive 5, 10. Apparently, postoperative radiotherapy does not seem to 
improve the survival rate, even though on this point, no agreement exists in the 
literature 6, 10, 51. Temam et al. recently found that in a group of 69 patients 
affected by HNMM, including 19 with primary OMM, postoperative radiotherapy 
was useful for increasing local control 66. Current postoperative radiotherapy for 
cutaneous melanoma delivers 30 Gy or 24 Gy, e.g., in five fractions of 6 Gy 
spread over 2.5 weeks or 3 weeks 67, 68. Other irradiation modalities such as 
intraoral mould (60Co, 192Ir, or 198Au), intraoral electron beam or interstitial 
brachytherapy have also been used 69.  
 
8.3 Other therapies 
Adjuvant chemotherapy with decarbazine, platinum analogs, nitrosureas, and 
microtubular toxins have been used for palliative purposes or for therapy of 
metastatic melanoma, but does not seem to influence survival 6. Umeda and 
Shimada 63, suggested dimethyl triazeno imidazole carboxamide (DTIC), 
nimustine hydrocloride (ACNU) or vincristine (VNC) as drugs of choice for 
postoperative chemotherapy. 
Anticancer therapy using IFN-γ and anti-Fas antibody has shown positive 
results against OMM cells in an experimental model 70.  
Systemic immunotherapy has been used as adjuvant or for palliation in the 
treatment of disseminated disease. Immunotherapy with IL-2 and other  
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cytokines is not associated with an enhanced survival rate 6. The definition of 
the so-called cancer testis antigens (CTAs) expression profile in OMM could 
lead to the development of a new vaccine-based therapy 11. Gene therapy is still 
in an experimental phase 71.  
 
9. Prognostic factors and survival 
From a prognostic point of view, clinical stage at presentation is probably the 
most important factor in determining outcome 51. In a study on 230 patients 
surgically treated for OMM, Liu et al. found that thickness of the tumour, cervical 
lymph node metastasis, presence or absence of ulceration and the anatomic 
sites were all independent risk factors 72. It has been calculated that nodal 
involvement in OMM reduces the median survival time from 46 to 18 months 2. 
Furthermore, a tumour thickness greater than 5 mm, presence of vascular 
invasion, necrosis, polymorphous tumour cell morphology and the inability to 
properly resect the lesions with negative margins have been associated with 
poor survival in patients with primary HNMM 2, 10, 51, 57, 73.  
Despite the improvement of surgical techniques and the introduction of new 
chemotherapeutic agents, prognosis of this malignancy remains poor. The 
generally advanced stage of the tumour at initial diagnosis leads to a poorer 
survival of patients with mucosal melanoma as compared to patients with 
cutaneous melanoma. and the presence of a vertical growth phase are 
associated with a reduced median survival rate 2.  
In different series, the actuarial 5-year overall survival rate for HNMM ranges 
from 21% to 40% 6 and for OMM it is 15% with a median survival of 25 months 
2. Gingival melanoma has a better 5-year survival rate than palatal melanoma, 
with a longer median survival period (46 months versus 22 months).2 
Recurrences may occur even 10–15 years after primary therapy. Distant 
metastases to the lungs, brain, liver and bones are frequently observed 74.  
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Abstract 
Purpose. To report the clinical, pathological and therapeutical experience with 
a group of patients with primary oral malignant melanoma (OMM). 
Patients. 14 patients (5 males, 9 females, mean age 57.9 years) with 
histopathological diagnosis of OMM were treated at the Department of Oral and 
Maxillofacial Surgery/Oral Pathology of the Vrije Universiteit Medical Centrum 
(VUmc) in Amsterdam between 1978 and 2005. A pigmented, flat or swollen, 
irregularly bordered lesion of oral mucosa was detected in most patients during 
the first clinical examination. Pain was the most commonly referred symptom. 
The palate was the most frequently affected subsite. Following the mucosal 
melanoma microstaging system all patients staged as stage I (TanyN0M0) 
could be subclassified as microstage II (invasion up to the lamina propria), 
except one who was microstaged as III (deep skeletal tissue invasion into 
skeletal muscle, bone or cartilage). Where possible, surgery has been the 
treatment of choice. Postoperative radiotherapy, using fractions of 6 Gy twice a 
week for a total dose of 3 30 Gy, was given to 3 patients. Three patients were 
primarily treated with radiotherapy alone. 
Results. Five patients developed a local recurrence within a period of 4 to 72 
months and 10 patients developed distant metastases within a period of 6 to 78 
months. Ten patients died of their disease within an average interval of 40 
months, with a range of 12 to 80 months. Of the 
ten patients who qualified for evaluation of the five-year-survival rate, one was 
alive with disease and two were alive without evidence of disease, which results 
in a five-year survival rate of 30%. However, all patients have died of their 
disease before the end of the ten-year follow-up period. 
Conclusions. Our study confirms that OMM is a rare and aggressive 
malignancy with a low five-year-survival rate. No evidence-based protocol is 
available for the best therapeutical approach. 
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1. Introduction 
The incidence of head and neck mucosal melanomas (HNMMs) is 
approximately four per 10 million population per year in the USA 1. Oral 
malignant melanomas (OMMs) represent about 1% of all melanomas and 
approximately the 0.5% of all oral malignancies. 2, 3. The neoplasm is more 
common in Japan and in some african regions (e.g. Uganda) than in Western 
countries 4, 5. The age of reported patients affected by OMM ranges from 20 to 
80 years and a male predilection has been observed 2, 3. OMM mostly affects 
the palate and the maxillary gingiva 1,3. The possible role of chronic trauma (e.g. 
ill-fitting dentures), tobacco habits or environmental pollution as “promoter” 
factors has not been established. It is largely unknown if UV light can have 
some effects on the oral mucosa biology (especially for mouth-breather 
patients) as it happens for the sun-exposed skin. Combinations of surgery, 
radiotherapy and chemotherapy for the management of OMM have variously 
been reported 3, 6, 7. The prognosis of this malignancy is extremely poor, with a 
five year survival ranging between 15% and 20% 1. Metastasis to the oral cavity 
derived from a primary melanoma elsewhere in the body, is extremely rare. 
In 1994 we have reported 8 cases of primary OMM treated at the Vrije 
Universiteit Medical Center (VUmc) in Amsterdam between 1978 and 1993 8. 
The present review is based on our experience with six additional patients 
referred to our institution between 1994 and 2005. 
 
2. Patients and Methods 
Clinical and histopathological data from 14 patients with a diagnosis of OMM, 
referred to the Department of Oral and Maxillofacial Surgery of VUmc in 
Amsterdam between 1978 and 2005, were included in this study. There were 
five males and nine females (table 1). The age of the patients ranged from 31 to 
91 years (average 57.9 years). 
At first clinical evaluation, presence of a pigmented, flat or swollen, irregularly 
bordered lesion of oral mucosa was noticed in 12 out of 14 patients while a non- 
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pigmented swelling was recorded in two cases (amelanotic melanoma). In three 
cases, lesions were superficially ulcerated. Colours observed were brown, black 
or purple. The size ranged from 0.3 to 1.8 cm in diameter. Pain was the most 
common referred symptom. The palate was the affected subsite in 9 out of 14 
patients (64%); in three cases the lesions were localized in the edentulous 
maxilla; one patient presented involvement of the buccal mucosa and one of the 
tongue. No reliable information was available about the presence or absence of 
pre-existing melanotic pigmentations in the oral subsite where OMM developed, 
except for one patient in whom a benign melanotic pigmented lesions was 
removed four years previously (patient 12) and another patient who had been 
irradiated six years before because of a malignant melanoma of the left cheek 
mucosa (patient 7). 
In all patients an incisional biopsy was performed. Immunohistochemical 
markers such as S-100 protein, gp100 (HMB- 45) and Mart-1 (Melan A) were 
used in case of doubt. Applying the histopatological system used in the 
WESTOP Banff workshop proceedings on OMMs 3 all but two lesions could be 
subclassified as in situ lesions with neoplastic activity limited to epithelium or to 
epithelial-connective tissue interface. Cases 6 and 14 were characterized by 
tumour extending within the underlying connective tissue. According to the 
clinical staging system  7, 9 (table 2), patients without regional lymph node 
metastases were subclassified as stage I (TanyN0M0) (13 patients), while one 
patient with clinical positive regional lymph nodes was staged as II (TanyN1M0). 
Following the mucosal melanoma microstaging system after Prasad et al. 10 
(table 2) all patients staged as I (TanyN0M0) could be subclassified as 
microstage II (invasion up to the lamina propria) except patient 6 who was 
microstaged as III (deep skeletal tissue invasion into skeletal muscle, bone or 
cartilage). 
Ten out of 14 patients received radical surgery without neck dissection as 
primary treatment. Simultaneous neck dissection was performed in one patient 
with preoperatively confirmed lymph node involvement. Postoperative  
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radiotherapy, using fractions of 6 Gy twice a week for a total dose of 30 Gy, was 
given to three patients. Three patients were primarily treated with radiotherapy 
alone. 
Disease specific survival rates were recorded after five and ten years, 
respectively. 
Table 1.  Relevant clinical features of fourteen patients treated between 1978 and 2005. 
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Table 2.  Clinical staging system for  OMM with histopathological microstaging for Stage I 10. 
 
3. Results 
Complete resection of the primary was achieved in 7 out the 11 patients that 
received surgery as first treatment (table 3). 
Five patients developed a local recurrence within periods of 4 to 72 months. 
None of these recurrent tumours could successfully be treated. 
Regional metastases were present in one patient at initial admission, while six 
patients developed such metastases within periods of 2 to 21 months. 
Treatment of such regional metastases consisted in most patients of radical 
neck dissection followed by radiotherapy. 
Distant metastatic spread occurred in 10 patients within periods of 6 to 78 
months. The most commonly involved sites were the lung, the mediastium, and 
the liver with rare metastatic spread to the adrenal glands, thyroid glands, 
pancreas, atrium and the skin. Some of these distant metastases were only 
disclosed at autopsy. In one patient a lobectomy was performed, 
unsuccessfully. In one other patient with lung metastases, treatment with 
dimethyl-triazeno imidazole carboxamide (DTIC) once every four weeks in a 
dose of 800 mg/m2 was administered. Although there was a good response of 
the lung lesions, the patient developed a metastasis in one of the adrenal 
glands and finally died of the disease. Yet two patients were unsuccessfully  
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treated for distant metastases in the lung and the liver with gammainterferon 
and interleukin 2. 
Of the 11 patients who had at least a follow-up of 12 months and of whom 
complete follow-up information was available, ten died of their disease within an 
average interval of 40 months, with a range of 12 to 73 months. Of the ten 
patients who qualified for the five-year-survival rate, seven had died of their 
disease, one was alive with disease and two were alive without evidence of 
disease. The latter 3 patients died of their disease within the ten-years follow-up 
period. 
The follow-up data are summarized in table 3. 
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Table 3. Follow-up  data of  14 patients. 
 
4. Discussion 
Most of the epidemiologic, histopathologic and clinical features of our patients 
were in accordance with those reported in the literature. The incidence in 
females was almost twice as high as in males, which is in contrast with the 
finding in a few other papers where a higher prevalence was reported in males 
2, 9. The palate was the most commonly oral subsite involved. 
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Our experience confirms that the spectrum of clinical manifestations of these 
rare tumours is extremely heterogeneous. The lesions can be solitary or 
multiple, flat and/or elevated (fig. 1), usually dark pigmented even though 
pigmentation can be completely absent (amelanotic melanoma) 3, 11. Borders of 
lesions are usually irregular and no clear demarcation exists between the tumor 
and the adjacent tissues. A melanocytic activity, clinically corresponding to a 
light brown-black pigmentation gradually fading in the surrounding mucosa, can 
be observed in most patients.  
 
 
 
Satellite foci around the primary may be present as well (fig. 2) giving some 
support to the theory of “field cancerization” already proposed for other 
histological types of malignancy 12.  
 
 
 
Figure 2. Malignant melanoma of the palate in a 33-year-old 
woman. Notice the separate pigmented area caudally. 
Figure 1. Malignant melanoma of the palate witha mixed  
flat/elevated clinical appearance. 
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Pain, superficial ulceration and bleeding were additional signs and symptoms 
recorded in our patients. One out of 14 (7%) of the patients in this series had 
regional lymph node involvement at the time of diagnosis. Data form the 
National Cancer Data Base (NCDB) USA, show that 27% of patients with 
malignant mucosal melanoma of the head and neck develop regional lymphatic 
metastases during the course of the disease 6,13. 
The existence of an “oral potentially malignant melanocytic lesion” has not 
clearly been defined and little is known about the pathobiological mechanism 
that leads to the development of OMM 14, 15. According to some authors about 
30% of OMMs are preceded by oral pigmentations for several months or even 
years 2, 16. It is interesting to notice that among pigmented lesions of oral cavity, 
oral nevomelanocytic nevi (OMNs) and OMMs are mostly localized in the palate 
17 and this finding may lead to the hypothesis that subtypes of OMNs could 
represent precursor lesions in the pathogenesis of OMM. Documentation on the 
presence of a pre-existing melanotic pigmentation in the same subsite where 
OMM developed was available only for one patient of our series. 
From the diagnostic point of view several procedures have been cited in the 
literature including cytological examination of brushed samples and clinical 
methods such as “rubbing a gauze” 18,  19. 
Histopathological examination of an incisional or excisional biopsy still 
represents the most accurate diagnostic tool. In the guidelines provided for the 
surgical management of cutaneous melanoma a diagnostic excisional biopsy of 
the suspected lesion is recommended followed by a wide local excision when 
the diagnosis is proven. 20-22. In the head and neck region, however, an 
excisional biopsy with a 1- to 2-mm margin for small lesions in amenable 
locations, or an incisional biopsy in case of a large lesion or a location in sites 
where an excisional procedure would involve extensive and mutilating surgery 
seem to be preferred because of the presence of anatomical limitations 23. In all 
the cases we faced, an incisional biopsy has been performed since the large  
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dimensions of the tumor and/or the close relationship to teeth or vital structures, 
precluded an excisional biopsy. 
It should be borne in mind that surgical diagnostic or therapeutical procedures 
performed on malignant neoplasms could hypotetically increase the risk of 
malignant cells spreading in the adjacent tissues (so-called “seeding”) or in 
other parts of the body through the blood or lymphatic stream 24,25. Such an 
iatrogenic dissemination might play a part in the pathogenesis of recurrences or 
distant metastases. Results from studies by Rampen et al. and Austin et al. 26,27 
show a somewhat reduced survival rate in patients with melanoma who had 
incisional biopsies. Conversely, results from a retrospective study on 265 
patients who had an incisional biopsy of cutaneous melanoma and 496 control 
cases of excisional biopsy, did not show such correlation 28; other authors seem 
to support these findings 29, 30. Five , 6 and 10 patients out of the 14 described 
in the present series respectively developed recurrences, regional and distant 
metastases. We are not able to quantify which role the incisional biopsy may 
have played in the development of metastases since such evaluation would 
require the measurement of the level of specific OMM markers in the blood 
stream before and after the biopsy. 
The value of the sentinel node biopsy for OMM has not been established. 
Adjunctive radiological diagnostic methods such as computed tomography, 
magnetic resonance imaging and positron emission tomography (PET) are 
sometimes useful. In a study on the all group of head and neck mucosal 
melanomas (HNMMs) Goerres et al. recently reported that PET scanning may 
have some value for staging purposes 31. 
From the histopathological point of view our experience confirms the usefulness 
of the WESTOP subclassification for uniform reporting and staging 3. The 
pathology report should also indicate the OMM cellular subtype as well as the 
presence of atypical findings. Our cases showed a wide range of cellular 
morphological features such as spindle, plasmacytoid, epithelioid and clear 
cells. In one of our patients we also observed and recently reported in detail the  
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extremely rare histological association between OMM and 
pseudoepitheliomatous hyperplasia 32. Presence of melanin pigment in the 
ductal epithelial cells of the underlying salivary glands was described in another 
case. This feature has rarely been reported and has previously been named 
“melanogenic metaplasia” 33. 
Complete excision of the primary tumour, with radiotherapy, chemotherapy or 
immunotherapy as adjuncts, has been the treatment of choice, although the 
value of adjuvant treatment has not been established. A 1-2 cm tumour-free 
margin, generally required and accepted for cutaneous melanoma, can rarely 
be applied in the oral cavity 23. Nevertheless, local control does not seem to be 
a strong predictor for survival and even after a presumptive radical excision of 
tumours many patients develop a recurrence 3, 7. Some factors potentially 
implied in the pathogenesis of recurrence may be related to the stimulation of 
tissues by growth factors after surgery and to the difficulty of obtaining a 
complete excision 6, 34. Thus, despite a presumptive radical surgery of the 
primary, the microscopic evaluation of the specimen may reveal the presence of 
atypical melanocytes in the margins. In the present evaluation, a radical 
excision of the primary was achieved in 7 of the 11 patients treated with 
surgery. Nevertheless all of them experienced recurrence and/or metastases 
(table 3). The question as whether the usual poor outcome of this disease 
should condition the surgical approach remains unanswered. 
The policy with regard to the treatment of the neck is still controversial. There is 
no evidence that prophylactic neck dissection enhances survival rate of patients 
with OMM 35, 36. According to Tanaka et al. 37, neck dissection should be 
reserved for cases with preoperatively confirmed lymph node metastases and 
the choice of the neck dissection modality should be guided by the extent and 
the level of the nodes 38. Six out of fourteen patients (43%) developed regional 
metastases during the follow-up. 
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Malignant melanoma has been generally regarded as a poorly radiosensitive 
malignancy 3,7. Data on the possible role of primary and postoperative 
radiotherapy in the management of OMM are scarce and mostly refer to the 
entire group of HNMM 9, 39. In a study on 35 patients affected by OMM primary 
radiotherapy appeared to be more effective than surgical treatment when the 5-
years cumulative survival rates were compared 37. Postoperative radiotherapy 
could be of some usefulness especially when prognostic pathologic features are 
poor (e.g. histopathological evidence of no radical excision or regional lymph 
node involvement). Teman et al. recently found that postoperative radiotherapy 
did improve local control in a group of 69 
patients affected by HNMM, including 19 patients with primary OMM 40. In the 
present report, 3 patients received primary radiotherapy and 3 had 
postoperative radiotherapy. This small number of patients does not allow to 
draw statistical conclusions on the effectiveness of radiation in the treatment of 
OMM. Adjuvant chemotherapy does not seem to influence survival 6. 
Prognosis of this malignancy remains extremely poor. In different series, the 
actuarial-5 year overall survival rate for HNMM ranges from 21% to 40% 6 and 
for OMM approximately 15% with a median survival of 25 months 1. Gingival 
melanoma seems to have a better 5-year survival rate than palatal melanoma, 
(46 months vs. 22 months of median survival period) 1. In the present report 
recurrences developed within a period of 4 to 72 months even though lesions 
occurring on the same subsite of the primary have been reported after 10-15 
years 38,  41. 
The relatively small number of included cases does not allow us to make 
significant statements about a possible relationship between staging, treatment 
and prognosis. Early diagnosis might be essential for successful treatment 
and is perhaps the key factor for improving the prognosis of OMM, but this still 
has to be proven. 
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Abstract 
Background: Pseudoepitheliomatous hyperplasia (PEH), a histological 
mimic of squamous cell carcinoma, is an exuberant reactive epithelial 
proliferation that may be induced by a variety of infectious, traumatic, 
inflammatory and neoplastic conditions of the skin and mucous 
membranes. PEH has been described in association with Spitz nevi and 
intramucosal nevi but not with oral malignant melanoma. 
Methods and results: A case of PEH in malignant melanoma of the 
palate in a 46 year old female patient has been described. A search of 
the English literature did not disclose any previously reported case of 
such event. 
Conclusions: PEH associated with oral malignant melanoma is 
apparently very rare and most likely originates from the surface 
epithelium. This is in contrast with PEH in cutaneous melanoma where 
follicular or eccrine units have been suggested to be the origin. 
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1. Introduction 
Pseudoepitheliomatous hyperplasia (PEH) or pseudocarcinomatous hyperplasia 
is a reactive proliferation of surface epithelium, occasionally occurring in a 
variety of infectious, traumatic, inflammatory, and neoplastic conditions of the 
skin or mucous membranes 1, 2. Diseases of the skin commonly associated with 
PEH include mycobacterial, fungal, and parasitic infections as well as chronic 
irritations and neoplasms1, 3. PEH has also been reported at the edges of 
chronic ulcers after burns or in stasis dermatitis1, 4. As stated by Hanly et al., 
Mott et al., and by Filho, association of PEH with melanoma of the skin has not 
been documented in detail 2, 3, 5.  
In the oral mucosa, PEH has been described in association with granular cell 
tumor and pleomorphic adenoma 6, 7. Dorji et al.8 and Suzuki et al.9 described 
Spitz nevi and intramucosal nevi of the oral cavity associated with PEH but, to 
the best of our knowledge, no case of oral malignant melanoma (OMM) with 
PEH has thus far been described. 
PEH of the skin is thought to represent a proliferation of squamous epithelium of 
follicular and eccrine units or the epidermis itself 3, 5, 6, 10, 11. Considering the 
absence of the follicular apparatus in the oral cavity, some authors have 
hypothesized a histogenic origin from minor salivary glands or ectopic 
sebaceous glands for PEH at this site 3, 12, 13.  
We report a patient with malignant melanoma of the oral cavity with associated 
PEH. 
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2. Case report 
A 46-year-old woman was referred to the Department of Oral and Maxillofacial 
Surgery for multiple areas of brown-black flat pigmentation involving the 
edentulous maxilla, partly located on the palate and partly on the adjacent 
alveolar ridge (Fig. 1). The patient was otherwise healthy. 
A biopsy of the most suspicious area on the anterior part of the palate showed 
malignant melanoma associated with PEH of the surface epithelium (Figs 2 and 
3). 
 
Figure 1. Malignant melanoma involving the palate and the maxillary  
gingiva. 
 
Figure 2. Histologic features of oral malignant 
melanoma in  association with 
pseudoepitheliomatous hyperplasia of the 
overlying epithelium, more or less masking the 
malignant melanoma cells (H&E _50; 
microstage level II). 
Figure 3. Pseudoepitheliomatous  
hyperplasia. Higher magnification  
(H&E 100). 
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Clinically, there were no signs of regional or distant metastases. CT scanning of 
the maxilla did not show destruction of the underlying bone. Further work-up, 
including CT of the thorax, did not show the presence of metastases. According 
to the TNM staging system proposed for mucosal melanoma of the head and 
neck (Stage I: localized disease; Stage II: regional metastases; Stage III distant 
metastases), 14 the patient was subclassified as Stage I. The histopathological 
microstaging of Clark, used in cutaneous melanoma, cannot be applied to oral 
mucosa because of the lack of histologic landmarks analogous to papillary and 
reticular dermis. A recently proposed microstaging system for Stage I 
recognizes three levels: 
 
1. Level I: pure in situ melanoma without evidence of invasion or in situ 
melanoma with microinvasion 
2. Level II: invasion up to the lamina propria 
3. Level III: deep tissue invasion into skeletal muscle, bone, or cartilage 15 
 
The present case has been microstaged level II. Treatment consisted of a 
maxillectomy. The defect was temporarily closed with a prosthesis. 
Two years later, a second malignant melanoma, most likely a second primary, 
was observed on the right cheek mucosa. This lesion was surgically removed 
as well. Two months later, a lymph node metastasis developed on the right side 
of the neck. Radical neck dissection with post-operative radiotherapy was 
performed. 
A few months later, local and regional recurrence was noticed. In addition, 
metastases were detected in the mediastinum, the lungs, and in the liver. The 
patient was treated with dimethyl triazino imidazole carboxamide chemotherapy 
once every 4 weeks in a dose of 800 mg/m2. A total of 15 courses of 
chemotherapy were administered. Clinically, there was a partial response, but 6 
months later a metastasis was diagnosed in one of the adrenal glands, the 
patient refused additional treatment, and died 1 year later.  
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3. Discussion 
The distinction between malignant melanoma with PEH and pigmented 
squamous cell carcinoma (SCC) can be difficult on routine hematoxylin–eosin 
sections. Histologically, PEH is characterized by irregular cords and nests of 
epithelial cells, extending into the underlying connective tissue. The irregular 
contour of nests and strands, hyperkeratosis and papillomatosis, and the 
presence of occasional squamous pearls and of mitotic activity may lead to an 
erroneous diagnosis of SCC 1, 2. The identification of the underlying disorder 
(e.g. granular cell tumor) and the absence of nuclear atypia, abnormal mitotic 
figures, or individual dyskeratotic keratinocytes are the key features that 
characterize PEH 2, 3. 
In the present case, the presence of both melanocytic and keratinocytic cells 
could also lead to the misdiagnosis of a tumor with biphenotypic characteristics 
such as OMM associated with SCC or pigmented SCC. However, the atypical 
cells of pigmented SCC show strong positivity for cytokeratin and are S-100 
negative 16. Our case was characterized by positivity with S-100 but not to 
cytokeratin, indicative of malignant melanoma associated with PEH. 
The origin of PEH in oral mucosa is unclear. Where for the skin a stimulated 
proliferation of squamous epithelium within follicular and eccrine units has been 
hypothesized, the same theory cannot be applied to the oral mucosa, because 
of the lack on non-hair-bearing squamous-lined mucosae of the follicular 
apparatus 3, 6, 10, 11. Even if a role of the so-called Fordyce's spots (ectopic 
sebaceous glands) could be postulated, we would stress the fact that some oral 
lesions typically associated with PEH (e.g. granular cell tumor) usually develop 
within oral sites in which these glands are uncommon (e.g., dorsal surface of 
the tongue). Some authors have also suggested a histogenic origin from minor 
salivary glands for PEH in this site, but there is no consensus in the literature 3.  
Several growth factors (EGF, TGF-α, TGF-β, bFGF, and PDF) and interleukins 
(IL-1, IL-6, IL-7, IL-8, IL-10, and IL-12) expressed by in vitro melanoma could 
provide the proliferative stimulus to the epithelial cells 17. Some authors have  
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emphasized the possible role of the epidermal growth factor receptor in the 
molecular pathogenesis of melanoma-associated PEH, but results from different 
studies are inconclusive 2, 18, 19.  
Although we cannot provide definitive proof of the structure giving rise to the 
PEH, we feel that its presence along much of the surface epithelium, in the 
absence of underlying salivary gland tissue, and as illustrated in Figs 2 and 3, is 
most compatible with an origin from the surface epithelium itself. 
In conclusion, although some studies on the rare association between 
cutaneous melanoma and PEH have been reported in the English literature, we 
were not able to find such as association for OMM 2, 3, 5, 20. The present case 
report documents this intriguing feature of PEH in association with OMM. 
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Abstract 
Presence of melanin pigment within the epithelial cells of minor salivary glands 
(“melanotic pigmentation”) is an exceptionally rare finding and to the best of our 
knowledge only one documented case, in association with a malignant 
melanoma, has been described. 
In the present paper, a case of melanotic pigmentation of the palatal minor 
salivary glands is reported. Four years later the patient developed a malignant 
melanoma at the junction of the hard and the soft palate.  
 
 
 
 
 101
Melanotic pigmentation of minor salivary gland 
 
1. Introduction 
Melanocytes are embryologically derived from the neural crest and are 
generally thought not to be constituents of normal salivary tissue 1, 2. However, 
Takeda documented the presence of pigmented cells, most likely melanocytes, 
in 1.8% of 445 specimens from autopsies and biopsies of human minor salivary 
glands 3. Melanin-containing cells have also been observed within salivary gland 
tumours as well as in minor salivary glands adjacent to oral malignant 
melanoma (OMM) 2, 4, 5. Phagocytosis and transfer of melanin from melanocytes 
to other cells types are the two possible explanations for the presence of 
melanin pigment within the cytoplasm of non-melanogenic cells.  
The present case reports the finding of melanotic pigmentation of the  ductal 
cells of minor salivary glands of the palate in the presence of melanosis in the 
overlying mucosal epithelium and the subsequent development of an OMM, four 
years later. A review of the English literature disclosed only one somewhat 
similar case 5. 
 
2. Case report 
A 50-year-old man was referred to the Department of Oral and Maxillofacial 
Surgery/Oral Pathology of the Free University Medical Centrum in Amsterdam 
because of a pigmented lesion in the oral cavity. Intraoral evaluation showed 
the presence of a flat, irregularly-shaped, not uniformly pigmented lesion 
localized on the left side of the hard palate. The lesion was predominantly 
brown-black, measured approximately 1.5 cm and was surrounded by several 
minor brownish pigmentations (Figure 1). Symptoms were absent and no 
palpable regional lymph nodes could be detected in the neck. The medical 
history was essentially negative. The patient did not use any medication. He did 
not smoke and drank approximately one glass of wine per day. 
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Figure 1. “Melanotic macule” of the left side of the palate surrounded by minor  
satellite pigmentations. 
 
Under the tentative clinical diagnosis of melanotic macule an excisional biopsy 
was performed, that included the underlying periosteum. The defect was 
covered with a skin graft. Histopathological evaluation showed the presence  of 
melanin pigment in the basal layer of the mucosal epithelium. There were no 
distinct signs of  melanocytic atypia. In one of the underlying salivary gland 
lobules several pigmented epithelial cells were observed in the interlobular and 
excretory ductal cells. Morphology and architectural pattern resembled those of 
normal epithelial duct cells with the exception for the presence of 
intracytoplasmic pigment, staining positive for melanin (Figures 2 and 3). 
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Figure 2. Presence of melanin pigment within the ductal epithelium of a minor salivary 
 gland in the margin of the surgical specimen (H&E stain; x 50). 
 
 
Figure 3. Presence of melanin pigment within the ductal epithelium of a minor  
salivary gland.(H&E stain; x 100). 
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Follow-up visits were scheduled twice a year. After four years, a white-yellowish 
soft tissue mass, surrounded by pigmentation, was noticed in the midline at the 
junction of the hard and the soft palate (Figure 4). An incisional biopsy was 
performed and histopathological evaluation revealed the presence of a truly 
invasive malignant melanoma. Further work-up, including a CT -thorax, did not 
show the presence of regional or distant metastases, resulting in Stage I, 
according to Patel et al. 6. Treatment consisted of a partial maxillectomy. The 
surgical margins were free in all directions and there was no bone invasion. 
One year later there was a local recurrence and at the same time a pancreatic 
metastasis was detected. The patient died one year thereafter.  
 
Figure 4. Oral malignant melanoma developed four years after the diagnosis of possible 
neoplastic melanocytic proliferation with extension of melanin into the salivary ductal cells. 
 
3. Discussion 
OMM is a rare and aggressive neoplasm of melanocytic origin, accounting for 
about 1% of all oral malignancies 7. Approximately one third of OMMs are  
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preceded for months or years by a melanotic macule but the histopathologic 
nature of such entity is still poorly understood 8. Oral melanocytic naevi (OMNs) 
and OMM display similar epidemiological features such as age at occurrence 
and the frequent involvement of the palate 9. However, in the present case there 
has been no evidence of a pre-existing melanocytic nevus.  
Presence of melanin pigment within the epithelial cells of minor salivary glands 
is an exceptional finding 5. The biological mechanism underlying this 
phenomenon is unknown although several hypotheses have been put forward 2 
,4, 5. Shivas and Maclennan excluded the concept of a phagocytic property of the 
salivary gland cells leading to the ingestion of melanin produced in melanocytes 
elsewhere 5. Instead, They interpreted their finding as melanogenic metaplasia 
of mucous cells. In the case of a pigmented mucoepidermoid carcinoma of 
minor salivary glands of the palate, Sekine et al. speculated about  the possible 
presence of a “migration factor” from cancer cells to pre-existing melanocytes 
acting as a stimulating factor for melanin production, being delivered to the 
adjacent cells 2. In another report of a pigmented pleomorphic adenoma and a 
pigmented mucoepidermoid carcinoma, Takeda et al. stated that quiescent 
melanocytes of salivary glands can be activated under certain conditions such 
as the presence of neoplastic changes 4, 11. Azzopardi et al. investigated 
melanin pigmentation in breast carcinomas and also mentioned the possible 
existence of a cancer cell-related factor stimulating the adjacent melanocytes 12. 
Sakaki et al. reported seven cases of “melanotic oncocytic metaplasia” of the 
nasopharynx, hypothesizing a neuropeptidergic stimulation of the melanocytes 
and a deposition of melanin within the metaplastic oncocytes 13. A possible 
stimulating influence of tobacco smoke on melanocytes was also mentioned by 
these authors 13. The phenomenon of melanocytic colonization of neoplasms, 
reported for malignancies on other sites, may probably occur also in salivary 
glands tumours 15. 
Takeda et al. identified pigmented cells, most likely melanocytes, in only 1.8% 
of 455 specimens from minor salivary glands 3. These cells were located in the  
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periductal and periacinar fibrous tissue close to the epithelial surface. They 
displayed a concentric-circular arrangement and were gathered in groups or 
presented as single cells not connected to epithelial cells 3. In another series, 
pigmented cells were observed in the interlobular duct of the parotid gland of 
only one out of 400 cases 14. In the present case, we were not able to 
demonstrate the presence of melanocytes around the pigmented duct cells. On 
the basis of the present knowledge we have no convincing hypothesis to 
explain the presence of melanin pigment within the salivary gland ductal cells. 
Most likely there has been a transfer of the melanin produced by epithelial 
melanocytes into the ductal cells of the underlying salivary glands. The concept 
of “melanogenic metaplasia” as being proposed by Shivas and Mclennan 5 is an 
interesting one. However, until now there is no scientific evidence to support 
such concept.  
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Abstract 
Pigmented nevi of the oral mucosa are rare benign melanocytic tumours. 
Epidemiological data are scanty, and the etiology and pathogenesis of these 
lesions are poorly understood. Reports are mainly based on isolated cases or a 
relatively small series of cases. Some reviews have drawn attention to the 
frequent localization of these lesions on the hard palate, the site of preference 
for oral malignant melanoma (OMM). However, as yet, there is no direct proof 
that oral melanocytic nevi (OMNs) constitute precursor lesions of OMM. 119 
cases of OMNs, registered at the nationwide Registry of Pathology (PALGA) in 
The Netherlands during the period 1980–2005, have been evaluated. 
Subepithelial OMNs were the most commonly recorded lesions (96 cases), 
followed by blue (10 cases), compound (7 cases) and junctional OMNs (5 
cases). Only one case of a combined nevus was recorded. None of the patients 
developed OMM during a mean follow-up period of 8.6 years. 
We present an analysis of this series of cases, together with a review of the 
literature. The findings of the present evaluation do not give support for the 
hypothesis of OMN being a marker for an increased risk of future development 
of OMM. 
 
 
 111
Oral melanocytic naevi 
 
1. Introduction 
Oral melanocytic nevi (OMNs) are benign tumours of melanocytes, the pigment 
producing cells found in the skin and in juxtacutaneous mucous membranes, 
including the oral mucosa 1. While cutaneous melanocytic nevi of young adult 
Caucasians number in the dozens, OMNs are rare, and their etiology and 
pathogenesis are poorly understood 2, 3. A Medline database search disclosed 
approximately 120 articles on OMNs published between 1965 and 2005, most 
of these being reports of isolated cases or small series of cases. In a review of 
the literature of 2004, Buchner et al. identified a total number of less than 300 
reported OMNs, to which they added a further 91 cases 3.  
The prevalence and incidence of OMNs have not been studied systematically. 
In Buchner’s study from northern California, OMNs represented 0.1% of about 
90.000 biopsies accessed at the Oral and Maxillofacial Pathology Laboratory 
during a 19-year period 3. The reported female to male ratio was approximately 
1.5:1. There was no racial preference. Age at diagnosis ranged from 3 to 
85 years 3-5.  
Regarding etiology and pathogenesis, most studies have focused on cutaneous 
lesions. It is now clear that melanocytic naevi constitute benign neoplasms of 
cutaneous melanocytes, which frequently harbour oncogenic BRAF or, less 
commonly, NRAS or HRAS mutations 6. Probably, oncogenic mutations drive 
the initial hyperproliferation that results in the formation of the naevus, while a 
subsequent growth-arrest response with the features of oncogene-induced 
cellular senescence accounts for the cessation of further growth 7, 8.  
Different from normal melanocytes which are regularly interspersed as single 
cells among basal keratinocytes, forming the so-called “epidermal-melanin unit”, 
nevomelanocytes tend to cluster in compact so-called theques 1, 9.  
In view of the many histologic similarities, it seems plausible that the 
pathogenesis of OMNs is similar to that of the cutaneous lesions. Regarding 
morphogenesis, the melanocytic proliferation can be divided into three phases: 
(1) proliferation of benign neoplastic melanocytes along the submucosal– 
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mucosal junction (junctional nevus); (2) migration of these cells to the 
underlying mesenchymal tissue (compound nevi); and (3) loss of the junctional 
component of the naevus, so that all remaining nevomelanocytes are located 
within the subepithelial compartment (subepithelial nevi) 1, 9, 10.  
Congenital melanocytic nevi are present at birth, while those developing after 
birth are referred to as acquired nevi 5, 11, 12. Probably, most melanocytic nevi of 
the oral mucosa are acquired 5. Reported size have ranged from 0.1 to, rarely, 
3.0 cm 4, 5. OMNs typically are well circumscribed round or oval macules, 
although slightly raised papules, and polypoid larger lesions have been reported 
as well 1, 4, 5. OMNs have been reported to occur multiple 13. Elevated acquired 
nevi are usually lightly pigmented, while flatter lesions tend to be more darkly 
pigmented 1. Colours vary from brown to blue, bluish-gray, or black; generally 
an individual lesion has a similar colour throughout 1, 4, 5, 14. Rare non-pigmented 
nevi are on record 15. The hard palate, buccal mucosa and gingiva are most 
commonly affected 3, 4, 5, 14, 16, 17. No data in the literature are available regarding 
presence of symptoms. OMNs are usually discovered during routine dental 
examinations. The clinical appearance is not diagnostic, so that a biopsy is 
usually required to exclude other pigmented lesions such as melanotic macula, 
amalgam tattoo and, most importantly, malignant melanoma 3.  
Similarly to their cutaneous counterpart, OMNs are classified in five types: (1) 
junctional; (2) compound; (3) subepithelial (sometimes referred to as 
intramucosal); (4) blue and (5) combined 5. In the junctional OMN, nests of 
nevomelanocytes are arranged along the epithelial–subepithelial junction. 
Compound and subepithelial nevi are characterized by sheets and cords of 
nevomelanocytes spreading into the underlying connective tissue. In the 
subepithelial type the nevus cells are entirely located in the connective tissue 
compartment, 1, 10 while in the compound nevus, the nevomelanocytes are 
partly arranged at the epithelial–subepithelial junction and partly in the 
underlying connective tissue. The blue nevus is characterized by subepithelial 
proliferation of generally pigmented, elongated, often bipolar, melanocytes,  
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often accompanied by some stromal fibrotic response and the presence of 
melanophages 18-20. Large, so-called plaque-type blue nevi have occasionally 
been reported 20. Another rare variant is the Spitz nevus, a subtype 
characterized mainly by the large size of the lesional cells 21, 22. Combined nevi 
show a combination of a blue nevus with another nevus type, usually a 
compound nevus 4, 5, 23.  
The aim of the present retrospective analysis is to report the epidemiological 
and pathologic features as well as the follow-up data of a series of 119 patients 
with OMNs from the files of the nationwide network and Registry of histo- and 
cytopathology (PALGA) in The Netherlands in the period between 1980 and 
2005. Since 1991 all pathologists in The Netherlands automatically report their 
diagnoses to that registry. In the period between 1980 and 1991 the 
participation rate gradually increased from 8% in 1980 to 45% and 96% in 1985 
and 1989, respectively. Permission was obtained to retrieve all registered cases 
of OMNs. 
 
2. Material and methods 
Data analyzed in the present retrospective evaluation were obtained from the 
files of the PALGA Registry of The Netherlands. Criteria adopted for the 
database search were based on the association of the term “nevus” with “oral 
mucosa”, “oral cavity”, “mouth” or “alveolar process”. Information on the age 
and gender, oral subsite, histologic diagnosis, and treatment were obtained. 
The search disclosed 809 cases recorded between 1st January 1980 and 31st 
December 2005 (Fig. 1). Of these, 137 lesions could be classified as intraoral; 
the other cases were located on the lips or the perioral tissues and were 
excluded from further evaluation. Lesions histologically diagnosed as 
“melanocytic hyperplasia”, “focal melanosis” or “melanocytic lesion” as well as 
“white sponge nevus” were excluded from the study. Thus, 119 cases remained 
for evaluation. 
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Figure 1. Criteria for the inclusion of the OMNs cases (1980–2005). 
 
All histopathologic reports were reviewed and OMNs were classified into five 
groups: junctional, compound, subepithelial, blue nevus and combined nevus 
according to accepted histologic criteria outlined above 1, 3-5, 10. Oral subsites 
were subclassified in seven groups: hard palate, soft palate, gingiva, 
mucobuccal fold, buccal mucosa, floor of the mouth and tongue. 
Follow-up data of the 119 patients were obtained from the PALGA Registry. The 
length of follow-up varied from 0.5 to 24 years the mean being 8.6 years. 
Endpoints included the date of 31st December 2005 or a diagnosis of OMM. 
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3. Results 
According to the present evaluation of the period 1991–2005, the annual 
incidence of excised OMNs in The Netherlands, is 4.35 cases per 10 million 
population per year. 
The relative frequency of the histopathologic types of the 119 OMNs is listed in 
Table 1. Ninety-six (80.6%) nevi were of the subepithelial type, while blue, 
compound, junctional and combined nevi accounted for 10 (8.3%), 7 (5.9%), 5 
(4.2%) and 1 (0.8%), respectively. The hard palate was the most frequently 
involved oral subsite (41 cases, 34.4%), followed by the mucobuccal fold (29 
cases, 24.3%), the gingiva (27 cases, 22.6%), the buccal mucosa (13 cases, 
11%), the soft palate (5 cases, 4.2%), the tongue (2 cases, 1.7%) and the floor 
of the mouth (2 cases, 1.7%). All OMNs from the gingiva and the soft palate 
were of the subepithelial type. Eight out 10 (80%) of the common blue nevi were 
localized in the palate or in the mucobuccal fold, while no such lesions were 
found in the gingiva. 
 
Table 1. Histopathologic subclassificasion of 119 OMNs 
 
 
The gender distribution of OMNs according to histopathologic type and oral 
subsite involved is presented in Table 2. Age of patients at the time of diagnosis 
ranged from 5 to 87 years. The age range of patients with subepithelial, 
compound, junctional and common blue nevi was 5–87 years (mean: 38 years), 
16–44 years (mean: 28.7 years), 7–52 years (mean: 28.6 years) and 31– 
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74 years (mean: 49.1 years), respectively. The only patient with a combined 
nevus was 38 years of age. In the group of patients younger than 30 years, 15 
lesions were located on the hard palate while only four affected the gingiva. 
Conversely, during the fourth, fifth and sixth decades, the distribution between 
these subsites was almost the same (hard palate: 22; gingiva: 21). Results from 
the same evaluation by gender are shown in Table 3. 
 
Table 2. Gender distribution of OMNs. 
 
 
Table 3. Age distribution (years) of OMNs according to the histological type. 
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Complete excision of the lesion was performed in 70 cases, while in 49 
instances an incisional biopsy was taken. Three out of the 70 excised lesions 
(4.3%) were reported to have incompletely removed. Presence of melanin 
pigment was mentioned in 20 cases. Ballooning of lesional melanocytes 
(presence of copious amounts of finely vacuolated cytoplasm), intralesional 
calcification, and mucinous degeneration of nearby minor salivary glands, were 
observed in three cases each. 
In none of the 119 patients concerned, an OMM was registered during the 
follow-up period. 
 
4. Discussion 
The PALGA Registry is rather unique in registering, since 1991, all 
histopathologic and cytopathologic diagnoses rendered in The Netherlands. For 
reasons of privacy only data on gender, date of birth and date of diagnosis are 
made available for research purposes, such as in the present case. The registry 
does not contain information on the date of death or the cause of death. 
Since the oral epithelial lining is considered part of the oral mucosa, the 
adjective subepithelial rather than intramucosal would seem more appropriate 
for describing those lesions entirely confined within the connective tissue. At 
present, melanotic nevi are considered to represent neoplasms rather than 
malformations, as has been previously thought 6.  
Subepithelial OMN is the most common histologic type, followed by blue nevus, 
compound, junctional and combined nevi. Even though some cases of Spitz 
nevi and epithelioid or plaque-type variant of blue nevi of the oral cavity have 
been reported,19-22 no such cases were disclosed in the PALGA data base. One 
case of balloon cell intramucosal-type nevus was encountered. This subtype of 
nevus, rarely described in the oral cavity, is characterized by nevomelanocytes 
with copious, finely vacuolated cytoplasm, caused by swelling of abnormal 
melanosomes, together with the presence of nevomelanocytes of usual 
appearance and melanophages at the lesional periphery 1, 24. When comparing  
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percentages of our study with those from the study of Buchner et al., 
subepithelial nevi are more frequent in the present series (80.6% vs 55%), while 
the frequency of blue nevi is lower (8.3% vs 32%) 5. 
OMNs were more frequently biopsied in females (F:M = 1.5:1); it is, however, 
unclear whether this means that OMNs are really more frequent in females. 
Seven out of 10 blue nevi occurred in women; this contrasts with other studies 
where a predilection of blue nevi in men has been reported 3, 8.  
The hard palate is the most common subsite affected by OMNs, followed by 
mucobuccal fold and gingiva. Involvement of the tongue and the floor of the 
mouth is exceptional (4 cases out 119, 3.5%). Two out of 4 of lesions at these 
oral subsites were blue nevi. Our data confirm a distinct predilection of OMNs 
for the upper part of the oral cavity,3-5, 14 a feature that is shared with oral 
melanoma and differs from that of epithelial neoplasms of the oral mucosa. 
In accordance with the literature, our data indicate that junctional and combined 
nevi are mostly found in young individuals; 75% of the lesions (9 out of 12) were 
from patients under 40 years of age. Conversely, the peak incidence of 
diagnosis of subepithelial nevi is in the fifth decade (Fig. 2). 
 
 
Figure 2. Distribution of OMNs in relation to age. 
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These data support the idea that melanocytic nevi go through a junctional and a 
compound phase before they become subepithelial.3-5, 9, 14 All 10 common blue 
nevi were found in patients over 30 years of age (Table 4). 
 
Table 4. Age distribution (years) of OMNs according to oral  subsite. 
The present evaluation shows that location of OMNs seems to be significantly 
related to both age and gender. The reason of the differences of topographical 
distribution between males and females remains unknown (Fig. 3). 
No data on the potential malignant transformation rate of OMNs are available as 
they are for the cutaneous counterpart 5, 25, 26. About one third of OMMs are 
preceded by oral pigmentations for months or even years, but the histologic 
phenotype of such presumed precursor lesions remains to be reported in detail 
26-28. The apparently strong correspondence between oral subsites affected 
either by OMNs and OMMs (hard palate, mucobuccal fold, gingiva) may 
constitute an indirect argument supporting the idea that some OMNs do 
progress to OMM. In the present study all oral melanocytic nevi have been 
excised. Therefore, the question as whether such nevi, if left untreated, may in 
time transform into a malignant melanoma, remains unanswered. None of the 
patients developed a malignant melanoma in the oral cavity in an admittedly 
short mean follow-up period of 8.6 years. Since the PALGA Registry does not 
contain information about the date of death, the figure of the mean follow-up 
period may not be completely accurate. Nevertheless, the present evaluation  
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does not provide concrete support for the idea that the presence of an oral 
melanocytic nevus indicates a risk of future development of OMM. 
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Abstract 
Background. Treatment of head and neck mucosal melanoma (HNMM) 
remains a challenge. Surgery has traditionally been the main therapeutic 
approach. The role of postoperative radiotherapy has never been clearly 
established. 
Methods. The experience with a group of 42 patients (16 males; 26 females) 
with a primary HNMM is reported. 
Results. Eleven out of 19 patients (57.9 %) receiving surgery alone developed 
a regional lymphatic metastasis. For patients receiving postoperative 
radiotherapy (19 cases), regional metastatic spread occurred in 4 cases (21%). 
Percentages of local failure were 57.9 % (11/19) and 26.3 % (5/19)  for patients 
treated with surgery alone and for those treated with surgery and radiotherapy, 
respectively. 
Distant metastases occurred in 10 out of 19 patients (52.6 %) receiving surgery 
alone and in 9 out of 19  patients (47.3 %) receiving both therapies.  
Conclusions. The present evaluation confirms a poor prognosis for patients 
with HNMM, independent from the treatment modality. 
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1. Introduction 
Head and neck mucosal melanoma (HNMM) is a rare and aggressive neoplasm 
of melanocytic origin 1. This malignancy was firstly described by Weber in 1859 
and recognized as a distinct clinical entity, named “melanotic sarcoma” in 1869 
2. HNMM accounts for 8-15% of all head and neck malignancies, including 
cutaneous melanomas, representing 0.2-10% of all melanomas that may arise 
in the body 1-4. In the National Cancer Database of the USA, only 1.3% out of 
84,836 cases of melanoma were proven to be of mucosal origin and 611 (0.7%) 
of these were located in the head and neck region 5.  In their review, Manolidis 
and Donald, disclosed a total number of nearly 1000 cases reported in the 
literature up to 1997 6. 
It has been suggested that the incidence of mucosal melanomas is lower in 
geographic areas where cutaneous melanomas are more frequently observed 7, 
8. Furthermore, HNMM are apparently more common among Japanese and 
Ugandan Africans than among Caucasian populations. 7,9,10. There is no distinct 
gender predilection 6, 11,  although a few authors reported a female 
preponderance in their series 12, 13. The etiology and pathogenesis are still 
obscure; this also applies to the role of possible precursor lesions 11, 14, 15. The 
clinical manifestations are rather heterogeneous and the histopathologic 
appearance is sometimes bizarre 6, 11, 16. HNMMs are rated among the most 
malignant tumours of the human body with a 5-year survival rate for nasal, 
pharyngeal, oral and sinus melanomas of 30.9, 13.3, 12.3 and less than 5.0 
percent, respectively 6, 13, 17-20. 
Here we report our experience with a group of 42 patients with a primary HNMM 
referred to the VU University Medical Center in Amsterdam, the Netherlands, 
and to the Academic Hospital of Parma University, Italy, during the past 30 
years together with a discussion on the role of postoperative radiotherapy. 
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2. Patients and Methods 
Clinical and histopathological data from patients affected by HNMM and 
referred to the Otolaryngology/Head and Neck Surgery and to the Oral and 
Maxillofacial Surgery/Oral Pathology departments of the VU University Medical 
Center in Amsterdam, the Netherlands, and to the Oral and Maxillofacial 
Surgery department of the Academic Hospital of Parma University, Italy, 
between 1976 and 2006 were retrieved and analyzed. Patients with a neck 
lymph node metastasis from cutaneous melanoma or from an unknown primary 
and patients with a metastasis to the head and neck region from a primary 
located elsewhere in the body were not included in the study.  
Forty-two patients (16 males and 26 females, m:f = 1:1.6) qualified for the 
evaluation. Age at diagnosis ranged from 31 to 91 years (mean age 63.7 years). 
The epidemiological data are summarized in table 1. 
 
Table 1. Epidemiological features of 42 patients affected by HNMM. 
Gender Age (years) 
Site of primary Number of cases m f m (mean) 
f 
(mean) 
total 
(range and mean) 
Sinonasal tract 
 
Nasal cavity 
Paranasal sinuses 
Nasopharynx 
25 (59.5%) 
 
18 
5 
2 
10 
 
7 
2 
1 
15 
 
11 
3 
1 
67.4 66.9 37 to 88  mean 67.1 
Oral cavity 17 (40.5%) 6 11 64.3 55.8 31 to 91  mean 58.8 
Total 42 (100%) 16 26 66.2 62.2 62.7 
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Clinical data included anatomic subsite (nasal cavity and/or paranasal sinuses, 
nasopharynx, oral cavity and lymph nodes of the neck), signs and symptoms, 
macroscopic appearance and presence of regional lymph nodes and/or distant 
metastasis at the time of diagnosis. Twenty-five out of 42  patients (59.5 %) 
were affected by a primary sinonasal mucosal melanoma (SNMM), the 
remaining 17 cases (40.5 %) being diagnosed within the oral cavity. 
Where available, additional information such as smoking habits and alcohol 
intake were collected. Tumour size and presence of neck node metastases 
were variously evaluated through clinical and radiological examination including 
CT-scan, MRI and ultrasound. Possible presence of distant metastasis was 
assessed through chest films, total body CT-scan or bone scintigraphy. All 
cases were re-staged according to the mucosal melanoma staging system : 
Stage I primary tumour present only (T any N0 M0); Stage II, tumour metastatic 
to regional lymph nodes (T any N1 M0) and Stage III tumour metastatic to 
distant sites (T any N any M1) 21-24.  
In all patients an incisional biopsy had been taken and the diagnosis was made 
on conventional H&E stained sections and, in case of doubt, with the use of 
immunohistochemical markers ( S-100, HMB45, Melan A).  
Histopathologic reports from biopsies and surgical specimens as well as 
surgical reports were reviewed and data regarding melanoma subtype and 
radicality of the surgical excision were recorded. All patients with stage I 
disease were microstaged according to the histopathologic staging system for 
stage I mucosal melanomas 24. 
Three out of 42 patients were primarily treated with radiotherapy alone and one 
patient refused treatment. The remaining 38 patients received surgery with or 
without post-operative radiotherapy.  
One patient received pre-operative radiotherapy. Chemotherapy and 
immunotherapy were administered in some cases for the treatment of 
disseminated disease and for palliative purposes. 
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For 35 patients complete follow-up data were available. The length of follow-up 
varied from 2 to 80 months, the mean being 27.8 months. Endpoint of data 
collecting was the date of  June 30th, 2006. 
Kaplan-Meier survival curves were generated and logrank tests were used to 
evaluate the differences between the overall and disease-specific survival rates. 
Comparisons of incidence of local and distant metastases as well as local 
failure were statistically determined through the Fisher’s exact test.  A p- value < 
0.05 was considered of statistical significance.  
 
2.1 Clinical presentation 
Clinical signs and symptoms of patients with SNMM included nasal obstruction, 
facial swelling, epistaxis and pain. At clinical evaluation, presence of a black-
brown polypoid mass invading the nasal cavity, the paranasal sinuses with 
radiological evidence of bone destruction was often reported. In some cases, 
the tumour was growing in the nasopharyngeal area and in few cases the 
lesions were reported as non-pigmented. For patients with OMM, presence of 
pigmented flat or swollen, often ulcerated lesion accompanied by pain and 
bleeding were the most frequently reported manifestations. Complete 
information on smoking habit and alcohol intake were available for 22 out of 42 
patients. Of these, 9 were smokers (at least 20 cigarettes/day). Only in 2 
patients a positive history of alcohol abuse was recorded.  
 
2.2 Histopathology and microstaging 
The differential histopathologic diagnosis based on conventional stained 
sections (H&E) included a variety of tumours such as poorly differentiated 
squamous cell carcinoma, lymphoma, esthesioneuroblastoma, 
rhabdomyosarcoma and unspecific diagnoses like “malignant necrotizing 
tumour”, “malignant subepithelial tumour” or “poorly differentiated tumour”. In 22 
lesions immunohistochemistry was performed; 17 stained positive for S-100  
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protein and 8 for HMB45. Lesions positively reacting to both markers were 5. 
Eight out of 42 lesions (19 %; 6 SNMM, 2 OMM) were amelanotic melanomas.  
Twenty-seven patients (13 SNMM; 14 OMM) and 11 (10 SNMM; 1 OMM) were 
microstaged as level II and level III respectively, according to the microstaging 
system for stage I mucosal melanoma (level II : invasion up to the lamina 
propria and level III deep skeletal tissue invasion into skeletal muscle, bone or 
cartilage) (Table 2) 24. 
 
Table 2. Relationship between histopathologic microstaging* for Stage I, level II and level III 
patients and local recurrence, regional and distant metastatic spread. 
 
Patients 
Regional 
metastasis 
Local recurrence Distant metastasis 
 
Patients with  microstage 
level II 
(27 Patients) 
 
12 
(44.4%) 
13 
(48.1%) 
14 
(51.8%) 
 
Patients with microstage 
level III 
(11 Patients) 
 
2 
(18.1%) 
4 
(36.3%) 
4 
(36.3%) 
P value 0.1596 0.7210 0.4848 
 
*  Level I :  Pure in situ melanoma without evidence of invasion or in situ melanoma with 
“microinvasion” ; not such cases included in the present study 
   Level II :      Invasion up to the lamina propria 
   Level III :    Deep skeletal tissue invasion into skeletal muscle, bone or cartilage 
 
No statistically significant differences are observed between microstage levels II and III. However, a 
decreased incidence of regional and distant metastasis, as well as local failure can be outlined for 
microstage level III patients. 
 
2.3 Treatment of the primary and radicality 
Thirty-eight patients underwent surgical excision of the tumour as the treatment 
of choice. Simultaneous neck dissection was performed in the two patients with 
preoperatively confirmed lymph node involvement. In 19 cases, additional  
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postoperative radiotherapy was administered. Three out of  42 patients were 
treated by radiotherapy alone. One patient refused treatment. 
Depending on the extension of the primary and the subsite involved, the 
surgical approach included lateral rhinotomy, nasal septum resection, partial or 
total maxillectomy, partial glossectomy or a combination of these. Laser 
treatment was used in one case of SNMM with involvement of the maxillary and 
sphenoid sinuses in which general conditions of the patient precluded other 
treatments. Such a treatment was not curative and the patient had a recurrence 
and died 8 months after therapy. 
 According to the evaluation of the surgical and the histopathological reports, 
radicality after excision of the primary was achieved in 23 patients (15 SNMM; 8 
OMM). In 11 cases no radicality was obtained (7 SNMM; 4 OMM). For 4 
patients the data on radicality were not available. 
The most frequently adopted scheme of postoperative radiotherapy consisted of 
600 cGy twice a week for a total dose of 3000 cGy. 
 
3. Results 
3.1 Local recurrence and metastatic spread 
Seventeen out of 42 patients (40.4%; 10 SNMM – 40%; 7 OMM –  41.1%) 
experienced local failure (development of a recurrence and/or of a second 
primary) after a period of time ranging between 1 and 72 months (mean 20.4 
months; mean SNMM: 10 months; mean OMM: 35.4 months) from the therapy. 
Recurrences were usually treated by surgery, in some cases followed by 
radiotherapy. 
Fourteen out of 42 patients (33%; 7 SNMM – 28%; 7 OMM – 41.1% ) developed 
regional lymph node metastases during follow-up, in a period ranging between 
2 and 39 months (mean 14.2 months: mean SNMM: 13.5 months; mean OMM: 
15 months). For patients with SNMM, the involvement of the neck was 
homolateral in 5 cases, contralateral  in one case and bilateral in another. Neck 
metastases mainly occurred in the submandibular region (5 cases), the others 
being localized in the submental, subdigastric or infraclavicular areas.  
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Treatment of these neck metastases mainly consisted of radical neck dissection 
followed by radiotherapy. Extranodal spread was reported in 2 cases. 
Twenty-one out of 42 patients (50%; 11 SNMM – 44%, 10 OMM – 58.8%) 
developed single or multiple distant metastases in a mean period of  21.2 
months (ranging between 0 to 78 months; mean SNMM: 16.5 months; mean 
OMM: 26.4 months ). The most commonly involved sites were the lungs (8 
patients) and the bone (6 patients). Other sites of distant metastatic spread 
included brain, liver, breast, pancreas and subcutaneous tissues. Therapy 
strategies for metastatic disease were mainly based on chemotherapy with 
dimethyl-triazeno-imidazole carboxamide (DITC), fluorouracil (5-FU) and 
doxorubicin (L-DOX), immunotherapy with gamma-interferon and interleukin 2, 
or on a vaccine prepared from the neoplastic cells.  
 
3.2 Follow-up and survival rates; microstaging and prognosis 
Overall and disease-specific 2-year and 5-year survival rates were evaluated for 
patients with SNMM, OMM  and for the whole group of patients with HNMM 
(Table 3; overall and disease-specific 2-year survival rates for OMM = 62.5% 
and 66.6%; overall and disease-specific 2-year survival rates for SNMM = 
38.8% and 53.8%; overall and disease-specific survival rates for HNMM = 50% 
and 60.7%. Overall and disease-specific 5-year survival survival rates for OMM 
= 38.4% and 41.6%; overall and disease-specific 5-year survival rates for 
SNMM = 0%; overall and disease-specific 5-year survival rates for HNMM = 
17.2 % and 21.7 %). The Kaplan-Meier survival curves show a statistically 
higher 5-year survival rate for patients affected by OMM as compared to 
SNMM. (Logrank test : P = 0.0227; 95% CI : 0,1610 to 0,8718). (Figures 1 and 
2) 
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Table 3. Two-year and 5-year overall and disease-specific survival rate for the patients with 
SNMM, OMM and for the whole group of patients with HNMM. 
 
2-year survival rate 5-year survival rate 
Site of the 
primary 
Overall Disease-specific Overall Disease-specific 
SNMM 38.8% 53.8% 0% 0% 
OMM 62.5% 66.6% 38.4% 41.6% 
HNMM 50% 60.7% 17.2% 21.7% 
 
 
 
 
 
 
 
 
Figure 1. Overall 5-year survival rate of patients affected by OMM and SNMM. 
(Logrank test : P = 0.0227; 95% CI : 0,1610 to 0,8718). 
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Correlations between histopathological microstaging and occurrence of regional 
metastasis, local failure and development of distant metastases are shown in 
Table 2. Histopathologic microstage levels did not significantly correlate with 
any of the parameters evaluated (P value for regional metastases = 0.1596; P 
value for local failure = 0.7210; P value for distant metastases = 0.4848), even 
though a decreased incidence of negative events can be outlined for patients 
with microstage level III. 
The Kaplan-Meier survival curves do not show a difference in the overall and 
disease-specific 5-year survival rates for patient with microstage level II and III 
(Logrank test : P1 = 0.2919; 95% CI :  0,1786 to 1,6784. P2 = 0.2254; 95% CI : 
0,1037 to 1,8257) (Figures 3 and 4). 
 
 
 
Figure 2. Disease-specific 5-year survival rate of patients affected by OMM and 
SNMM. 
(Logrank test : P = 0,0643; 95% CI : 0,1475 to 1,0566). 
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Figure 3. Kaplan-Meier estimator for patients with microstage level II and III 
(overall 5-year survival rate). 
(Logrank test : P = 0.2919; 95% CI :  0,1786 to 1,6784). 
Figure 4. Kaplan-Meier estimator for patients with microstage level II and III 
(disease-specific 5-year survival rate). 
(Logrank test : P = 0.2254; 95% CI : 0,1037 to 1,8257). 
 137
Head and neck mucosal melanoma 
 
3.3 Surgery versus surgery + postoperative radiotherapy 
Data on the comparison between patients treated with surgery alone or in 
association with radiotherapy are summarized in Table 4. Eleven out of 19 
patients (57.9 %) receiving surgery as only treatment for the primary developed 
a regional lymphatic metastasis (mean time of occurrence : 14.5 months). On 
the other hand, in the group of patients receiving postoperative radiotherapy (19 
cases) metastatic spread to the lymph nodes of the neck occurred in 4 patients 
only (21%; mean time of occurrence : 13.75 months)  (P = 0.0448). 
 
Table 4. Surgery versus surgery + postoperative radiotherapy. 
Treatment of the 
primary 
Regional 
metastasis Local failure 
Distant 
metastases 
Surgery 
(19 Patients) 11 (57.9 %) 11 (57.9 %) 10 (52.6 %) 
Surgery + 
radiotherapy 
(19 Patients) 
4 (21 %) 5 (26.3 %) 9 (47.3 %) 
P value 0.0448 0.0991 1.000 
 
A statistically significant difference is observed between patients receiving surgery and patient 
receiving surgery and postoperative radiotherapy with regard to regional metastasis. A not-
statistically significant decreased incidence of regional and distant metastasis, as well as local 
failure can be outlined for patients treated with postoperative radiotherapy. 
 
Percentages of local failure were 57.9 % (11/19; mean time of occurrence 24.5 
months) and 26.3 % (5/19; mean time of occurrence 9.4 months)  for patients 
treated with surgery alone and for those treated with surgery and radiotherapy, 
respectively (P = 0.0991). 
Distant metastases occurred in 10 out of 19 patients (52.6 %; mean time of 
occurrence 26.3 months) receiving surgery alone and in 9 out of 19 (47.3 %;  
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mean time of occurrence 15.6 months) patients receiving both therapies (P = 
1.000).  
A lesser incidence of regional and distant metastasis, as well as local failure 
was observed for patients treated with surgery and postoperative radiotherapy. 
The Kaplan-Meier estimator, however, shows a statistically significant better 
prognosis for patients receiving surgery alone (Logrank tests : P = 0.0028; 95% 
CI :  0,1162 to 0,6396)  (Figures 5 and 6).  
Data on stage at diagnosis (including microstage) as well as on radicality of 
surgery, separately evaluated for the two groups, are reported in tables 5 and 6. 
 
 
 
 
 
 
Figure 5. Overall 5-year survival for patients treated by surgery and surgery + 
postoperative radiotherapy. 
“S” = Surgery; 
“SR” = Surgery + radiotherapy; 
(Logrank test : P = 0.0028; 95% CI :  0,1162 to 0,6396). 
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Table 5. Relationship between treatment and stage at diagnosis (including microstaging for 
Stage I *). 
Stage at diagnosis 
Treatment of the 
primary 
I-II* I-III* II III 
Surgery 
(19 Patients) 14 (73.6%) 4 (21%) 1 (5.2%) No patients 
Surgery + radiotherapy 
(19 Patients) 10 (52.63%) 7 (36.8%) 1 (5.2%) 1 (5.2%) 
 
* Level I :  Pure in situ melanoma without evidence of invasion or in situ melanoma with 
“microinvasion” ; not such cases included in the present study; Level II :      Invasion up to the 
lamina propria;   Level III :    Deep skeletal tissue invasion into skeletal muscle, bone or cartilage 
Figure 6. Overall 5-year survival for OMM and SNMM patients treated by surgery 
and surgery + postoperative radiotherapy. 
“OS” = OMM treated with surgery; 
“OSR” = OMM treated with surgery + radiotherapy; 
“SNS” = SNMM treated with surgery; 
SNSR = SNMM treated with surgery + radiotherapy; 
(Logrank test : P = 0,0129) 
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Table 6. Relationship between treatment and radicality after the surgical excision of the 
primary. 
Radicality after the surgical excision of the primary 
Treatment of the 
primary 
Radical Not radical No data 
Surgery 
(19 Patients) 14 (73.6%) 3 (15.8%) 1 (5.2%) 
Surgery + radiotherapy 
(19 Patients) 9 (47.3%) 8 (42.1%) 2 (10.5%) 
 
4. Discussion 
Most of the epidemiological and clinical data analyzed in the present study are 
comparable to those reported in the literature 4, 21, 25-27. The peak incidence of  
HNMM is between the sixth and the seventh decade. In the present series, 
OMM seems to affect patients younger (mean age 58.8 years) than patients 
with SNMM (mean age 67.1 years). Women with OMM were significantly 
younger than men (mean age of 55.8 and 64.3 years respectively). No distinct 
gender predilection was found. 
Nasal obstruction, epistaxis and pain are the most frequently reported 
symptoms in patients with SNMM 6, 27. A diagnostic delay, probably mainly 
related to patients attitudes, ranging between 2 months and 2 years from the 
appearance of the first symptoms, was recorded in different series 6. OMM 
usually presents as a painful pigmented swelling, even though flat lesions or 
non-pigmented masses are sometimes described (amelanotic melanoma). Both 
SNMM and OMM are often ulcerated 28, 29. 
The role of tobacco habits and formaldehyde exposure as risk factors for 
inducing abnormal melanocytic differentiation has been hypothesized by some 
authors 6, 30. In the present series, chronic tobacco use was recorded only in a 
few patients. In contrast to melanoma of the skin, the pathogenesis of HNMM  
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seems to be based on genetic mechanisms unrelated to ultraviolet light 
exposure 31. The close anatomic proximity of the commonly affected head and 
neck mucosal sites (nasal cavity and paranasal sinuses and the palate) may 
lead to the hypothesis that the pathogenesis of these tumours is related to 
some abnormality during the embryogenesis of this region  32. 
Approximately one third of OMMs are preceded by localized pigmentation for 
months or years 11. The nature of such precursor lesions has not been clearly 
established yet. A recent evaluation on 119 patients with oral melanocytic nevi 
(OMNs) did not show an increased risk for OMM development 15.  
The present experience confirms the rather variable histopathological 
appearance of HNMM. In many of the cases, a definitive diagnosis could only 
be obtained with the use of specific markers such as antivimentin, S-100, 
NKI/C-3 and HMB-45. The histopathologic differential diagnosis mainly included 
poorly differentiated squamous cell carcinoma, lymphoma and sarcoma.  The 
use of electronic microscopy may provide some help in the demonstration of 
premelanosomes 6. 
Differently from its cutaneous counterpart, where a radical excision can often be 
achieved, the management of HNMM still represents a challenge. The often late 
diagnosis, anatomical limitations that preclude the possibility of a radical 
excision, and probably a more malignant biologic behaviour, negatively 
influence the success of treatment and the prognosis 33, 34. 
The limited size of most reported series and the heterogeneity of data do not 
enable to assess the effectiveness of the various treatment modalities with 
regard to variables such as local control, metastatic spread and survival rates 
35. Surgery has traditionally been the main therapeutic approach for the 
treatment of this malignancy 35. The role of postoperative radiotherapy in the 
management of HNMM has not yet been clearly established and the results of 
various studies on this subject remain controversial 1, 25, 35-37. Because of the 
rarity of this neoplasm it will be difficult to perform a randomized-controlled trial 
for a critical evaluation and comparison of the two treatment modalities. As a  
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matter of fact, most of the studies in the literature are retrospective analyses 
performed on small series of patients and these evaluations are biased by the 
lack of randomized selection criteria, as is the case in the present series. 
 In the present evaluation the number of patients who experienced regional 
and/or distant metastases as well as a local failure is higher among those who 
did not receive postoperative radiotherapy. In particular, the percentage of neck 
lymph node metastases seems to be significantly decreased by the 
administration of radiotherapy. Surprisingly, the analysis of the overall 5-year 
survival rate through the Kaplan-Meier estimator, demonstrates a better 
prognosis for patients treated by surgery without postoperative radiotherapy. 
This observation holds true when the analysis is separately performed for 
patients with SNMM and patient with OMM (Figures 5 and 6). These results 
may probably be explained through the evaluation of data on the radicality after 
excision of the primary (table 4). In fact,  the resection of the tumour was radical 
for 14 out 19 (76.3%) patients in the group receiving surgery alone. This 
percentage is significantly decreased in the group of patients treated with post-
operative radiotherapy (47.3%; 9 out of 19 patients). Stage at diagnosis 
(including microstaging) does not seem to be different in the two groups (table 
5). These findings are in accordance with some other previously reported 
studies. Lund et al. did not find any statistical difference of the overall survival 
rate in a group of 58 patients with SNMM treated with surgery or with surgery 
and radiotherapy 36. In a retrospective analysis on  48 patients affected by 
HNMM, Owens et al. showed that the addition of radiotherapy to surgical 
treatment leads to an improvement of locoregional tumour control 35. Similarly, 
Temam et al. reported a significant higher local control rate for patients 
additionally treated with postoperative radiation 25. However, in most of the 
reported series, local control was not associated with an increased survival rate. 
An exception is the study by Kingdom and Kaplan who observed an increased 
survival rate among patients treated with surgery and radiotherapy compared to 
those treated by surgery alone 38. 
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The low number of stage II and stage III patients (regional disease and distant 
metastases, respectively) in the present series does not allow to draw any 
statistically significant conclusions about the relationship between stage at 
presentation and prognosis. The observation by Prasad et al. that the 
histopathological microstage for stage I disease, reflecting tumour progression 
within the surrounding tissues, is a predictor of survival 24, is not supported by 
the results of the present study. 
The results of the present evaluation confirm a poor prognosis for patients 
affected by primary HNMM, independent from the treatment modality, being 
surgery alone or surgery followed by radiotherapy. In particular, the overall 5-
year survival rate for the whole group of HNMM of 17.2% seems to be slightly 
lower compared with those reported in other studies 8,  18,  21,  36,  37,  39-41. 
A site specific difference was noticed with regard to survival. Patients with OMM 
seem to have an higher disease-specific 5-year survival rate compared to 
patients with SNMM (38.4 % and less than 5 percent respectively). It is 
debatable if this difference depends on factors such as the histopathological 
microstage for stage I tumour (56.5 % of patients with SNMM had a microstage 
level III while only 6.6% of patients with OMM had the same microstage level) 
since such a microstaging system does not seem to correlate with the survival-
rate in the present evaluation.   However, these results are in contrast with 
some reports where melanoma arising in the nasal mucosa appears to have a 
better prognosis 17. 
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Summary and conclusions 
The diagnostic procedure of pigmented lesions of the oral cavity and perioral 
tissues is a challenging one. Even though epidemiology may be of some help in 
orientating the clinician and even though some lesions may confidently be 
diagnosed on clinical grounds alone, such a diagnosis remains “provisional”. A 
definitive diagnosis usually requires histopathological evaluation. Occasionally, 
immunohistochemical stains such as melanocyte marker HMB-45 and 
macrophage marker CD68 may be required to arrive at a correct diagnosis. 
The so-called ABCD checklist (“Asymmetry”, “Border” irregularities, “Color” 
variegation and “Diameter” > 6mm) that is commonly used to aid in the 
identification of cutaneous melanoma may also be of some help in the clinical 
diagnosis of oral malignant melanoma (OMM). Rapidly growing pigmented 
lesions should always be biopsied. Location on the palate increases the rate of 
suspicion of melanoma and usually requires a biopsy or long-term follow-up.  
A critical analysis of the literature on human OMM discloses a lack of thorough 
knowledge on the etiology and pathogenesis of this malignancy as well as a 
lack of evidence on the best therapeutical approach. The hypothesis that 
inhaled environmental carcinogens, including tobacco and formaldehyde, may 
have some influence in promoting an abnormal melanocytic proliferation is 
based on few epidemiological observations. Most of the reports do not include 
data on the presence or absence of exposure to carcinogenetic factors. p53 
protein alterations have been identified in about two-thirds of OMM. 
Surgical excision is the most frequently reported treatment for OMM. Surgery 
could be combined with radiotherapy, chemotherapy or immunotherapy even 
though the effectiveness of such therapies either as primary treatment or in 
association with surgical treatment is largely unknown.  
The Amsterdam experience with 14 patients affected by OMM confirms the 
extremely malignant and aggressive behaviour or this neoplasm. Five patients 
developed a local recurrence within a period of 4 to 72 months and 10 patients 
developed distant metastases within a period of 6 to 78 months. Ten patients  
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died of their disease within an average interval of 40 months, with a range of 12 
to 80 months. Of the ten patients who qualified for evaluation of the five-year 
survival rate, one was alive with disease and two were alive without evidence of 
disease, which results in a 30% five-year survival rate. However, all patients 
have died of their disease before the end of the ten-year follow-up period. 
From the histopathological point of view it seems remarkable to report a case of 
OMM associated with pseudoepitheliomatous hyperplasia (PEH). The presence 
of both melanocytic and keratinocytic cells could lead to the misdiagnosis of a 
tumour with biphenotypic characteristics such as OMM associated with 
squamous cell carcinoma (SCC) or pigmented SCC. The presence of PEH 
along much of the surface epithelium, in the absence of underlying salivary 
gland tissue, appears to point at an origin of the PEH from the surface 
epithelium itself. 
In another case, the presence of melanotic pigmentation of the palatal minor 
salivary glands was documented four years before a diagnosis of an OMM of 
the palate was established. Presence of melanin pigment within the epithelial 
cells of minor salivary glands is an exceptional finding and the biological 
mechanism underlying this phenomenon is unknown. The concept of 
“melanogenic metaplasia” as being proposed by Shivas and Mclennan is an 
interesting one. However, until now there is no scientific evidence to support 
such concept. It is questionable whether melanotic pigmentation of the palatal 
minor salivary glands represents a potentially malignant disease. 
Data from the literature show that about 30% of OMM are preceded by mucosal 
pigmentation for several months or even years. Some of these flat precursor 
lesions consist of cytologically atypical melanocytes and may in fact constitute 
the preinvasive macular phase of melanoma. 
The apparently strong correspondence between oral subsites affected either by 
oral melanocytic naevi (OMNs) and OMMs (hard palate, mucobuccal fold, 
gingiva) may constitute an indirect argument supporting the idea that some 
OMNs do progress to OMM. 
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However, the results of our own study do not confirm the hypothesis that the 
presence of an OMN indicates a risk of future development of OMM. In fact, 
None of the 119 patients with a diagnosis of OMN developed a malignant 
melanoma in the oral cavity in a mean follow-up period of 8.6 years. 
With regard to the whole group of patients affected by head and neck mucosal 
melanoma (HNMM), oral malignant melanoma seems to affect patients at a 
younger age (mean age 58.8 years) than patients with sinonasal mucosal 
melanoma (SNMM) (mean age 67.1 years). The number of patients who 
experienced regional and/or distant metastases as well as a local failure was 
higher among those who did not receive postoperative radiotherapy. In 
particular, the percentage of neck lymph node metastases seems to be 
significantly decreased by the administration of radiotherapy. Surprisingly, the 
analysis of the overall 5-year survival rate through the Kaplan-Meier estimator, 
showed a better prognosis for patients treated by surgery without postoperative 
radiotherapy. A similar result was shown when the analysis was separately 
performed for patients with SNMM and patients with OMM. Because of the 
retrospective nature and the incompleteness of the clinical records no clear 
guidelines were provided with regard to the indication for postoperative 
radiotherapy in the individual patients. A bias of the present evaluation may be 
represented by the fact that melanomas with an apparently intrinsic worse 
prognosis (e.g. SNMM) are overrepresented in the group of patients receiving a 
combined treatment.  
Unfortunately, the rarity of this neoplasm makes it rather unrealistic to perform a 
randomized-controlled trial for a critical evaluation of the role of postoperative 
radiotherapy.  
The observation by Prasad et al. that the histopathological microstage for stage 
I disease of OMM, reflecting tumour progression within the surrounding tissues, 
is a predictor of survival, is not supported by the results of the present study.  
The overall 5-year survival rate for the entire group of HNMM patients of the 
present series is 17.2%. A site specific difference was noticed with regard to  
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survival. Patients with OMM seem to have an better disease-specific 5-year 
survival rate than patients with SNMM. 
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Samenvatting en conclusies 
De diagnostiek van gepigmenteerde lesies van de mond en omgevende 
structuren kan bijzonder lastig zijn. In veel gevallen lijkt het verantwoord om op 
grond van bijvoorbeeld de leeftijd, de localisatie, de anamnese en het klinische 
aspect op alleen klinische gronden tot een diagnose te komen, maar in 
sommige gevallen is toch behoefte aan een meer zekere diagnose met behulp 
van weefselonderzoek. Het kan daarbij nodig zijn om immuunhistochemische 
kleuringen toe te passen, zoals de melanocytenmerker HMB-45 en de 
macrophagenmerker CD68, naast bijvoorbeeld routinematige kleuringen zoals 
de ijzerkleuring. De in de Engelse literatuur bekende ABCD checklist, waarbij 
de A staat voor asymmetry, de B voor border irregularities, de C voor 
verschillen in kleur en de D voor diameter ( > 6 mm) die wordt gebruikt bij de 
diagnostiek van melanomen van de huid is ten dele ook toepasbaar bij het 
maligne melanoom van het mondslijmvlies. Snel groeiende gepigmenteerde 
lesies dienen echter altijd te worden gebiopteerd. Localisatie van de 
pigmentatie op het palatum verhoogt de verdenking op de aanwezigheid van 
een maligne melanoom of eventueel een voorstadium daarvan en maakt 
derhalve een biopsie en/of langdurige controle noodzakelijk. 
Een kritische analyse van de bestaande literatuur over het orale maligne 
melanoom laat zien, dat er eigenlijk geen goed inzicht is in de etiologie en de 
pathogenese van deze kwaadaardige tumor. Bovendien zijn er geen 
betrouwbare gegevens beschikbaar over de beste manier van behandelen. Ten 
aanzien van de etiologie wordt door sommigen gesuggereerd, dat schadelijke 
stoffen uit het milieu carcinogeen kunnen zijn; het gaat daarbij in het bijzonder 
om tabakrook en formaldehyde. Er zijn echter maar weinig studies van het 
maligne melanoom van het mondslijmvlies die iets over deze factoren 
vermelden. Daarnaast wordt in sommige studies melding gemaakt van 
veranderingen in het p53 gen. 
Chirurgische verwijdering is de meest gangbare behandeling van een maligne 
melanoom van het mondslijmvlies. Chirurgische behandeling kan worden  
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gecombineerd met bestraling, chemotherapie of immuuntherapie. De 
effectiviteit van dergelijke aanvullende behandelingen in combinatie met 
chirurgie of als enkele behandelmodaliteit is nooit met zekerheid aangetoond. 
In het onderzoek naar 14 patiënten met maligne melanoom van het 
mondslijmvlies, gediagnosticeerd in een periode van ruim 30 jaar op de 
afdelingen mondziekten en kaakchirurgie en keel-, neus- en oorheelkunde van 
het VU medisch centrum te Amsterdam blijkt duidelijk sprake van het 
kwaadaardige agressieve karakter van deze tumor. Vijf patiënten ontwikkelden 
een locaal recidief binnen een periode van 4-72 maanden en tien patiënten 
ontwikkelden metastasen op afstand, dat wil zeggen buiten het hoofd-
halsgebied, binnen een periode van 6 tot 78 maanden. Tien patiënten zijn aan 
hun ziekte overleden binnen een gemiddeld interval van 40 maanden (spreiding 
12-80 maanden). 
Van de tien patiënten van wie de 5-jaarsoverleving kon worden nagegaan, 
bleek er na vijf jaar één in leven te zijn met de ziekte, terwijl twee patiënten in 
leven waren zonder aanwijzingen voor aanwezigheid van de ziekte. Hoewel het 
bij kleine getallen niet verantwoord is om de gegevens in percentages uit te 
drukken, zou het voorgaande betekenen dat er sprake is van een 5-
jaarsoverleving van 30%. Alle patiënten zijn uiteindelijk binnen tien jaar aan hun 
ziekte overleden. De bevinding vanuit de literatuur dat de voorgestelde 
histopathologische microstadiëring voor stadium I (maligne melanoom van 
mondslijmvlies, ongeacht de maximale afmeting, maar zonder aanwijzingen 
voor metastasering) voorspellende waarde heeft voor de overleving, werd niet 
bevestigd door de resultaten in het huidige onderzoek. 
Een ander aspect van het onderzoek betrof onderzoek naar maligne 
melanomen van andere slijmvliezen in het hoofd-halsgebied, in het bijzonder 
van de neus- en neusbijholten. Er werd daarbij een vergelijking gemaakt tussen 
de behandelingsresultaten van patiënten met een maligne melanoom van het 
mondslijmvlies en die met een maligne melanoom van de neus- en 
neusbijholte. Opvallend genoeg bleek dat patiënten met een maligne  
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melanoom van het mondslijmvlies gemiddeld ongeveer tien jaar jonger waren 
dan de patiënten van de andere groep. De 5-jaarsoverleving was voor patiënten 
met een maligne melanoom van het mondslijmvlies beter dan voor patiënten 
met een maligne melanoom elders in het hoofd-halsgebied. Daarbij zij echter 
opgemerkt, dat het om relatief kleine aantallen patiënten gaat. 
Verder bleek dat de kans op locaal recidief en/of regionale en 
afstandsmetastasering groter was bij patiënten, die niet werden nabestraald. 
Verrassenderwijs bleek echter de 5-jaarsoverleving voor patiënten die alleen 
met chirurgie waren behandeld – dus zonder postoperatieve bestraling – beter 
te zijn dan voor patiënten die werden nabestraald. Gelet op het retrospectieve 
karakter van het onderzoek en het op sommige plaatsen niet volledig zijn van 
de patiëntendossiers ten aanzien van de indicatie voor postoperatieve 
bestraling, kan geen betrouwbare uitspraak worden gedaan over de mogelijke 
waarde van postoperatieve bestraling bij het orale maligne melanoom. Gelet op 
de relatieve zeldzaamheid van het maligne melanoom in het hoofd-halsgebied 
is het niet zonder meer mogelijk een prospectieve studie op dit gebied uit te 
voeren. 
In ons onderzoek hebben wij melding gemaakt van een nogal ongewone casus 
van een maligne melanoom van het mondslijmvlies waarbij tevens sprake was 
van pseudo-epitheliomateuze hyperplasie. Er waren in de betreffende casus 
een aantal argumenten, die het inderdaad het meest waarschijnlijk maakten dat 
hier sprake was pseudo-epitheliomateuze hyperplasie van het overliggende 
plaveiselepitheel en dat het niet ging om een plaveiselcelcarcinoom met 
melaninepigmentatie. 
Een andere bijzondere casus die in ons onderzoek werd opgenomen, betrof 
een patiënt met melaninepigmentatie in de kleine speekselklieren van het 
gehemelte. Bij deze patiënt werd vier jaar later een maligne melanoom op de 
betreffende plaats gediagnosticeerd. Aanwezigheid van melaninepigment in 
epitheliale cellen van kleine speekselklieren is uitzonderlijk en er is geen goede 
verklaring voor dit fenomeen. In de literatuur wordt wel de term "melanogene  
 157
Samenvatting en conclusies 
 
metaplasie" genoemd, maar er is weinig wetenschappelijke ondersteuning voor 
een dergelijk concept. Verder is de vraag of het aantreffen van 
melaninepigment in kleine speekselklieren inderdaad als een potentieel 
kwaadaardig fenomeen moet worden beschouwd. 
Uit de literatuur blijkt, dat ongeveer 30% van het maligne melanoom van het 
mondslijmvlies geassocieerd is of mogelijk jarenlang voorafgegaan is door 
pigmentatie van het mondslijmvlies. Er kan daarbij sprake zijn van 
aanwezigheid van atypische melanocyten zonder dat op dat moment de 
diagnose maligne melanoom kan worden gesteld. De aanwezigheid van 
dergelijke atypische melanocyten lijkt als een pre-invasief stadium van een 
maligne melanoom te oeten worden beschouwd. 
Een naevus naevocellularis, zoals deze op de huid kan voorkomen, komt een 
enkele maal ook in de mond voor. De voorkeursplaats van orale naevi komt 
sterk overeen met die van een maligne melanoom. Het ligt daarom voor de 
hand om te veronderstellen, dat orale naevi wellicht voorloperlesies zijn van een 
maligne melanoom van het mondslijmvlies. Uit een landelijk onderzoek, waarbij 
dankbaar gebruikgemaakt is van het landelijke geautomatiseerde bestand van 
de pathologen (PALGA) werd echter geen ondersteuning voor deze hypothese 
gevonden. Geen van de 119 patiënten met een naevus naevocellularis van het 
mondslijmvlies heeft in een gemiddelde nacontrole periode van 8.6 jaar een 
maligne melanoom ontwikkeld. 

 159
 
Curriculum Vitae 
 
Pregraduation 
 
-   Born in Nardò (Lecce - Italy) 07/12/1977. 
 
-  Maturità Scientifica at “Leonardo da Vinci” Scientific Lyceum in 
Maglie (Lecce) 1996. 
 
- Three-month course of English language at Pitzer College 
(member of the Claremont Colleges), Los Angeles (CA) in 
2001. 
 
-  Graduated in dentistry (D.D.S.) at University of Parma (Italy) on 25/02/2002 (after two 
years of internship at the Oral Pathology and Medicine Department). Full votation 
(110/110 cum laude). 
Thesis title : “Epidemiology and clinical manifestations of gingival overgrowth in a 
group of 121 renal transplant recipients immunosuppressed with cyclosporine”. 
 
Postgraduation 
 
-  Postgraduated course of Oral Pathology and Medicine at University of Milan (Prof. 
Antonio Carrassi) in 2003. 
 
-  Postgraduated course of Oral Pathology and Medicine at University of Florence (Prof. 
Giuseppe Ficarra) in 2004. 
 
-  Full-time clinical activity at the Oral Pathology and Medicine Department (Prof. Paolo 
Vescovi) of the University of Parma, from 2002 to 2004. 
 
-  Ph.D. student at the Department of Oral and Maxillofacial Surgery/ Oral Pathology of 
the Free University medical center / ACTA (Prof. Dr. Isaäc van der Waal), in 
Amsterdam from 2004 to 2007. 
 
-  Clinical training in Oral Medicine at the Department of Oral Medicine of the University 
of San Francisco (Prof. Sol Silverman Jr., Prof. Francina Lozada-Nur). October-
November 2006 
 
-  Member of  SIPMO (Italian Society of Oral Medicine and Pathology) since 2002. 
 
-  Member of  SIOCMF (Italian Society of Oral and Maxillofacial Surgery) since 2002. 
 
-  Member of the EAOM (European Association of Oral Medicine) since 2004. 
 
-  Member of the SFOPOM ( Scandinavian Society of Oral Medicine and Pathology) 
since 2005 
 
-  Currently is “Contract Professor” of “Clinical Stomatology” at the School of  
Dentistry of  the Medical Faculty of the University of Parma. 

 161
Acknowledgements 
 
   “If I have seen further it is by  
standing on the shoulders of giants” 
     
              Sir Isaäc Newton 
 
 
 
 
Prof. Dr. Isaäc van der Waal. Dear Professor van der Waal, it is really 
hard even trying to find some words to express my feelings of gratitude 
for everything You thaught me. 
The knowledge, the passion and the devotion for the Oral Pathology, 
Medicine and Surgery that You transmitted me, are simply the most 
precious things that I received throughout my whole life.  
 
Prof. Paolo Vescovi. Caro Paolo. Eccomi qui, a distanza di pochi anni 
dalla tesi di laurea, a ringraziarti ancora. Senza il tuo costante appoggio 
ed il tuo aiuto non sarebbe stato immaginabile realizzare questa 
esperienza eccezionale. A te devo l’incalcolabile merito di avermi 
“iniziato” e pazientemente condotto per mano nell’apprendimento e nella 
pratica della nostra disciplina. Grazie Paolo. Maestro. Amico. 
 
Dr. Jacques Baart. Dear Dr. Baart, It has been a pleasure to have the 
possibility to spend a lot of working and social time with you and your 
family. Thank you for the beautiful moments and emotions. 
 
Prof. Dr. Charles R. Leemans. Dear Professor Leemans, I thank you 
very much for the support and help during my work. Your contribution 
has been essential for clarifying a lot of issues related to the head and 
neck mucosal melanoma. 
 
Prof. Dr. Wolter J. Mooi. Dear Professor Mooi, thank you very much for 
all the scientific imputs, help and collaboration you gave me throughout 
the preparation of the present thesis.  
 
 
 162
Prof. Dr. Mauro Bonanini. Caro Professor Bonanini, La ringrazio di cuore 
per il supporto e l’incoraggiamento che mi ha fornito durante la 
permanenza in Olanda e nella fase finale di studio effettuata a Parma. 
Grazie per avermi dato la possibilità di continuare a formarmi. Grazie per 
l’affetto e la fiducia costantemente dimostrati nei miei confronti  
 
Prof. Dr. Silvia Pizzi. Cara Silvia, ti esprimo la mia gratitudine per 
essermi stata vicina durante tutta questa lunga esperienza di studio. 
Grazie per la visita al dipartimento e per i bellissimi giorni trascorsi 
insieme ad Amsterdam. 
 
Prof. Dr. Enrico Sesenna. Chiarissimo Professor Sesenna, desidero 
ringraziarLa di cuore per l’aiuto e il supporto nella stesura di alcuni 
capitoli di questa tesi. In particolare, Le esprimo la mia gratitudine per 
aver reso possibile la collaborazione scientifica tra i dipartimenti di 
chirurgia maxillo-facciale di Parma e di Amsterdam. 
 
The staff and the residents of the Department of Oral and Maxillofacial 
Surgery/Oral Pathology of the Vrije Universiteit Medisch Centrum at 
Amsterdam. Dear all, I just wanted to thank everyone of you for 
constantly making me feeling like home. I am indebted to everybody. I 
am particularly grateful to Dr. Schulten and Dr. Becking. A special 
thought goes to my roommates Dr. Carol Saridin and Dr. Marnix Bom 
and to my friends Dr. Jantien Bremmer, Dr. Roeland Wijs, Dr. Tim 
Forouzanfar, Dr. Christian Grientschnig, Dr. M. Gilijamse, Dr. Jurgen 
Bosgra, Dr. Luk Verdonschot. 
 
Dr. Ivo ten Hove and Dr. Hakki Karagozoglu. Dear Ivo and Hakki, I am 
really lucky to have two paranymphs as you. I will always remember all 
the magnificent working and social time spent together. 
 
Dr. Martijn van Steenbergen and Dr. Remi Allard. Dear Martijn and 
Remi, thank you very much for assisting and helping me throughout all 
the phases of this experience. You perfectly planned every aspect of my 
permanence at the Department.  
 
Prof. Dr. Elizabeth Bloemena.  Dear Professor Bloemena, I would like to 
thank you for the improvement I have had through your lessons at the 
Oral pathology Department. 
 
A particular thanking goes to Mrs Dini Chevalking and Mr Wilem de Jong 
at the Oral Pathology Department. 
 
 163
Prof. Dr. Sol Silverman Jr. and Prof. Dr. Francina Lozada-Nur. Dear 
Professors, I thank you very much for the enlighting experience in the 
Deapartment of Oral Medicine of the University of San Francisco. 
 
Dr. Maddalena Manfredi. Cara Maddalena, ti ringrazio per il sostegno 
che mi hai sempre fornito durante questo lungo e complesso periodo. Ti 
sono grato soprattutto per i consigli preziosi, maturati dall’esperienza 
durante lo svolgimento del tuo Ph.D. 
 
Un ringraziamento particolare va all’equipe di Patologia e Medicina 
Orale dell’Università di Parma e ai miei colleghi e amici con i quali ogni 
giorno condivido le gioie e i problemi: Dr. Elisabetta Merigo, Dr. 
Alessandro Ripasarti, Dr. Rebecca Guidotti, Dr. Carlo Fornaini. 
 
Ringrazio inoltre tutto il Personale Medico e Paramedico della Clinica 
Odontostomatologica dell’Azienda Ospedaliero-Universitaria di Parma. 
 
Dr. Luigi Corcione. Caro Gino, queste poche righe sono per testimoniarti 
il mio affetto e la mia riconoscenza per i lunghi pomeriggi passati davanti 
al microscopio. Grazie. 
 
Dr. Angelo Catellani. Caro Angelo, ci sono molte cose per le quali dovrei 
ringraziarti e sarebbe impossibile elencarle tutte. Con la tua gentilezza e 
cortesia hai saputo pazientemente tollerare gli impegni scientifici 
paralleli alla mia attività lavorativa al tuo fianco. Ti sono debitore. Grazie. 
 
Lady Olga van der Waal. Dear Lady van der Waal, I would like to 
express my gratitude for all the sweetness you always had for me and 
Diana and for all the pleasant days we spent together in Italy and in 
Holland.  
 
Dimitri van Versendaal. Dear Dimitri, you are the only one who 
completely shared all my social life in Amsterdam during the past years. 
It is not possible to forget all the situations and atmospheres we passed 
through. I will always store in my mind and in my heart the irripetible 
emotions we lived together. 
 
Panagiotis Vodinas. Dear Panos, it hard to forget a guy like you are. 
Thank you very much for all the happiness you brought in my life. 
 
Gabriele Surdo. Gabriele, amico, fratello di sempre. Le parole non sono 
mai bastate a chiarire la natura del nostro legame. Non basta la musica 
e non basta il cinema, non basta la poesia e non basta la pittura. Tu solo 
 164
sai cosa intendo. Grazie per l’incalcolabile e infinito sostegno che hai 
saputo darmi soprattutto quando eravamo lontani. 
Un sentito ringraziamento ad Ada Lolli. 
 
Gabriele Vizzi. Caro Gabriele, amico, compagno di mille avventure. 
Anche per te è difficile esprimere un ringraziamento con le parole. Ti 
voglio bene. Grazie. 
 
I miei pensieri di gratitudine vanno inoltre ai miei amici di Parma come 
Matteo, Anna, Donato, Laura, Luigi ,Marco, Margherita.  
 
Sentiti ringraziamenti alla “cupola” : Sandro, Fabio, Teo, Milo, Davide! 
Compagni eccezionali di studio e divertimento. 
 
E’ doveroso ringraziare tutti i miei parenti (elencarli tutti sarebbe 
impossibile!), il ricordo dei quali mi ha sostenuto nei momenti difficili. Il 
mio pensiero è particolarmente rivolto a Anna e Tommasa Mangia, 
donne eccezionali. Un saluto metafisico và anche ai miei nonni, Donato 
e Maria Meleti e Antonio e Vincenza Mangia. 
 
Un affettuoso ringraziamento ai genitori di Diana, Dr. Paolo Cassi e 
Dr.ssa Donatella Censori. 
 
 
Last but not Least 
 
Papà, Mamma, Stefano, Massimo. Ho sempre pensato di aver avuto la 
fortuna di essere nato e cresciuto nella più bella di tutte le famiglie. Oggi, 
a 30 anni dalla mia nascita ne ho la conferma. Grazie Papà, grazie 
Mamma per essere riusciti a creare qualcosa di così meraviglioso. 
 
Diana Cassi. Diana, pochi uomini hanno la fortuna di incontrare una 
donna come te. Io sono uno di loro. Il tuo costante appoggio ha reso 
possibile tutto questo. Grazie Amore mio. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Finito di stampare nel mese di Dicembre 2007 
da Copy & Press  S.r.l. - Pr 
